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Summary and aim of the thesis 
 
FSHD, an autosomal dominant disease, has been associated with reduced numbers (<11, 
alleles ≤41 kb) of D4Z4 repeats at 4q35. However, in the our previuos genetic studies, we 
observed that 3% of healthy individuals carry D4Z4 reduced alleles (DRA). Moreover, 
through a large genotype-phenotype study on a cohort of FSHD patients and families, we 
confirmed that DRAs correspond to several phenotypes with variable severity of the disease. 
We, also, observed that penetrance is incomplete and that the pattern of inheritance is not 
always autosomal dominant.   
The aim of the present study is to test the predictive significance of molecular variations in 
FSHD. 
For this, an accurate clinical research has been conducted in collaboration with the Italian 
Clinical Network for Facioscapulohmeral Muscular Dystrophy (FSHD). A detailed clinical 
characterization of probands and relatives, the analysis of disease penetrance and the  study 
of inheritance mode in FSHD families from the Italian National Registry for FSHD (INRF) 
has been personally performed.  
Initially we investigated patients with 1-3 D4Z4 repeats, which represent the lower extreme 
of the molecular diagnostic spectrum with the most relavant clinical expression. Notably, our 
detailed analysis highlighted  clinical variability also in this subgroup of patients.  
These observations have emphasized the concept that the molecular mechanisms leading to 
disease are still not clear and that the molecular markers proposed for FSHD diagnosis are 
not predictive of disease precense and/or severity.  
To dissect these clinical complexity, we designed a new Comprehensive Clinical Evaluation 
Form (CCEF), a clinical tool useful in describing in a harmonized manner the phenotypic 
spectrum observed among FSHD families. The CCEF permit to quantify the motor disability 
and defines clinical categories by the combination of different features: 1) subjects with 
typical FSHD phenotype (category A), 2) subjects with muscle weakness limited to scapular 
girdle or facial muscles (category B), 3) asymptomatic/healthy subjects (category C) and 4) 
subjects presenting clinical features not consistent with the FSHD (category D).  
Through the use of CCEF we decided to reevaluate the clinical spectrum of 154 proband and 
306 relatives carriers of 33-35 kb (7-8 rps) D4Z4 reduced alleles, which represent the higher 
extreme of the molecular diagnostic spectrum with a wide disease variability This study 
showed two main aspects: first, the majority of probands carrying 33-35 DRA (53%) had 
moderate phenotype with partial or mild facial involvement; in contrast about 40% showed a 
	 4	
prevalent shoulder girdle impairment or atypical phenotype. Therefore this clinical variability 
could be confounding for the differential diagnosis between the FSHD and a myopathy 
presenting with FHSD-like features. 
Second, the majority of relatives were non penetrant carriers. This result highlighted the 
necessity of additional parameters to evaluate the risk to develop the desease in relatives and 
the importance of an accurate genetic counselling. 
In conclusion in dissecting FSHD clinical complexity it is mandatory to associate clinical 
scales for the evaluation of the disability degree and a tool for the precise phenotypic 
classification.  
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SECTION 1: introduction 
 
1 CLINICAL FEATURES 
 
FSHD (OMIM #158900) is the third most common form of hereditary myopathy with a 
prevalence of 1 in 20.000 [Mostacciuolo et al, 2009]. The disease was firstly reported in 1862 
by Duchenne de Boulogne, who published a picture of an affected patient in his “Album de 
photographies pathologiques” [Duchenne, 1862]. Thereafter, Duchenne described the disease 
in the famous series of papers in Archives of General Medicine in 1869, which are often cited 
as the earliest reference of FSHD[Duchenne, 1869]. In 1885, Landouzy and Dejerine 
described in detail the clinical features of FSHD, which was also called “Landouzy-Dejerine 
form of muscular dystrophy”. FSHD was characterized by initial progressive facial, shoulder 
girdle and pectoral muscle weakness and atrophy, followed by the involvement of abdominal 
muscles with lumbar hyperlordosis and anterior leg muscles with steppage gait [Landouzy et 
al, 1885].  Subsequently, in 1982, the thesis of Padberg provided the first modern clinical 
description of FSHD families. Padberg inves 
 
tigated a group of 107 subjects from 19 families, including 73 subjects displaying clinical 
signs of FSHD, none of his patients had pelvic girdle or calf muscle weakness. This study 
provided the first evidence for wide clinical variability in FSHD patients, even within the 
same family [Padberg, 1982].  
In 1991 an International Consortium established the clinical, laboratory and genetic criteria 
for FSHD diagnosis. This work responded for the need of selecting families that could be 
included in the linkage analysis [Padberg et al. 1991] towards the identification of the FSHD 
gene.  
Four main criteria were identified:  
1) onset of the disease in facial or shoulder girdle muscles 
2) facial weakness in more than 50% of the affected family members 
3) autosomal dominant inheritance in familial cases 
4) evidence of myopathic disease in EMG and muscle biopsy in at least one affected 
member of a family  
By contrast were considered suggestive of alternative diagnosis the: 
1) involvement of extra-ocular, masticatory, pharyngeal and lingual muscles 
2) Onset in pelvic girdle muscles 
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3) regression of symptoms and signs 
4) presence of severe and diffuse contractures 
5) involvement of myocardium with presence of cardiomyopathy 
6) persistently high CK values above five times the upper limit 
 
It was reported that the clinically recognizable age of onset is often very variable. However, 
the mean age of recognizable onset, at least by clinical examination, was in the second 
decade. The involvement of facial muscles was considered necessary for diagnosis. The 
FSHD phenotype (figure 1) is characterized by muscle weakness starting with the facial 
district followed by the progressive involvement of scapular fixator, humeral, truncal and 
lower extremity muscles, typically in the anterior leg compartment, presenting with footdrop. 
Weak abdominal muscles result in a protuberant abdomen and contribute to the lumbar 
lordosis. Lower abdominal muscles are weaker than upper abdominal muscles, causing 
strikingly positive Beevor’s s sign [Awerbuch et al., 1990]. A notable distinctive feature of 
FSHD is that muscle weakness displays asymmetric distribution [Brouwer et al., 1993]. The 
creatine kinase (CK) level can be moderately increased or normal. Electromyography (EMG) 
and histological analysis reveal non-specific myopathic changes associated, in some cases, 
with neurogenic and/or inflammatory aspects [Lin et al., 1991; Dorobek et al., 2013]. Muscle 
magnetic resonance imaging (MRI) can be normal or can show muscles with abnormalities 
on T1-weighted MRI sequences, corresponding to areas of fatty fibrous replacement, or with 
areas characterized by increased signal on T2- short inversion recovery (T2-STIR) 
sequences, reflecting an increase in tissue water content, due to muscle oedema, without fat 
replacement [Tasca et al., 2012]. Ancillary features, such as sensorineural deafness or retinal 
vasculopathy have been also reported in infantile FSHD forms, but they are not to be 
considered decisive criteria for FSHD diagnosis [Trevisan et al., 2008 a, b]. In the first 
clinical descriptions, FSHD showed a fully penetrant autosomal dominant pattern with age-
dependent penetrance estimated to be >95% by age 20. In the symptomatic cases, the disease 
is progressive, tough the rate of progression is variable in the majority of cases. Rarely, there 
can be long periods of apparent arrest of progression [Lunt et al., 1989]. 
 
 
 
 
 
	 8	
 
 
Figure 1: Schematic representation of the FSHD phenotype. 
2 THE DISCOVERY OF DNA ALTERATIONS  
 
An International Consortium was organized for FSHD linkage analysis. At the first meeting 
of the Consortium, in 1988, an initial exclusion map for FSHD was constructed [Sarfarazi et 
al, 1989; Jacobsen et al, 1990]. In 1990 the FSHD gene was assigned to chromosome 4 by 
positional mapping in 10 Dutch families [Wijmenga et al, 1990]; the confirmation of this 
location was performed in other families and with additional probes [Upadhyaya et al, 1990, 
1991].  Wijmenga reported that a Variable Number Tandem Repeat structure (VNTR) locus, 
was the most closely linked to FSHD and established the location of the FSHD gene in the 
subtelomeric region of chromosome 4q [Wijmenga et al., 1991]. Later, Wijmenga identified 
a 3.3 kb tandemly repeated sequence (D4Z4) located at the 4q subtelomeric region that could 
be detected by hybridization of EcoRI digested DNA using the p13E-11 DNA sequence as 
probe. This study included 11 Dutch families, 6 de novo cases, 29 healthy individuals 
[Wijmenga et al., 1992]. The authors showed that in healthy individuals the majority (72%) 
of EcoRI fragments detected by the p13E-11 probe were larger than 28 kb, while in FSHD 
patients there was an over-representation of fragments smaller than 28 kb. It was also shown 
that 5 out of 6 affected individuals with unaffected parents carried a de novo p13E-11 allele 
smaller than 28 kb [Wijmenga et al., 1992].  
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Based on restriction fragment mapping and DNA sequencing, van Deutekom and coworkers 
confirmed that the rearrangements associated with FSHD result in deletion of integral 
number of repeat KpnI fragments, designated D4Z4 [van Deutekom et al, 1993]. 
In normal subjects the p13E-11 EcoRI alleles usually range from 40 kb to approximately 300 
kb (>10 D4Z4 units), whereas alleles of 35 kb or shorter (≤ 8 D4Z4 units) are present in the 
majority of either de novo or familial FSHD patients [Upadhyaya et al., 1993; Wijmenga et 
al., 1994, Deidda et al., 1996] (figure 2). 
 
 
 
Figure 2: Deletion of a defined number of D4Z4 units on chromosome 4 in FSHD patients. Schematic 
representation of the D4Z4 repeats on chromosome 4 of a normal individual and a FSHD patient. Having less 
than 11 D4Z4 units is considered pathological.	
2.1 Size of D4Z4 allele and clinical expression 
Since the discovery of the FSHD molecular defect, genotype-phenotype studies have been 
conducted in order to evaluate if the size of the EcoRI fragment could be correlated with the 
clinical manifestations and to assess its impact on the phenotypic expression.  
In 1995, Lunt and coworkers [Lunt et al., 1995a] reported the genotype/phenotipe analysis on 
14 FSHD families (carriers 19-30 kb DRA) and 25 clinically isolated cases (carriers 13-24 kb 
DRA). The study revealed a clear correlation between smaller fragment sizes and earlier age 
at onset. The median age at onset in sporadic cases resulted 6.9 years (range <1-16 years) and 
18 years (range 8-23) in familial cases. Interestingly, the authors also observed within the 
families a anticipation of age onset. However, it was hypothesized that this trend might be 
more a reflection of ascertainment bias than a biological anticipation.  
The authors proposed that FSHD families could be divided broadly into three groups:  
i) new mutation cases with early onset (range <1-16 years), severe presentation, and 
small fragment size ≤18 kb; 
ii) large 'typical' families with median onset age ranging from 8-22 years associated 
with fragment size of 19-30 kb;  
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iii) small families, often with a later onset presentation (median 15-23 years), or 
scapulohumeral presentation, in which a the 4q35-cosegregating fragment is of 
30-38 kb size. 
A study of Tawil and coworkers in 1996 [Tawil et al., 1996] confirmed the same results, by 
examining the genotype/phenotype correlation in clinically and genetically well-defined 157 
FSHD subjects. In particular, this analysis showed the presence of the anticipation and that 
the size of the deletion and the disease severity were closely related. 
In the genotype-phenotype correlation study performed by Tonini et al. in 2004 on 238 
subjects from 106 unrelated families, it was observed that individuals with larger fragments 
showed a mild course of the disease, while those who had the smaller ones were more 
severely affected. However, when genders were analyzed separately, this correlation was 
significant for females but not for males. 
In 2003, Butz and coworkers conducted a systematic study of 39 unrelated FSHD patients 
with borderline D4Z4 repeat numbers (9-11) and 102 healthy controls, in order to identify the 
molecular diagnostic cut-off point between FSHD cases and the control population. The 
results indicated that there was not a definite diagnostic cut-off point separating FSHD, 
FSHD-like myopathies and healthy controls. Therefore, the authors suggested the D4Z4 cut 
off of 8 repeats [Butz et al., 2003] In a more recent study of Statland and coworkers [Statland 
et al., 2015]	the group of patients with milder phenotype seems to be expandinged, including 
also 7-8 DRA carriers. 
In summary, the above studies showed an inverse correlation between the number of D4Z4 
repeats and the severity of the disease. Alleles with 1-3 D4Z4 repeats are generally associated 
with a severe form of disease that presents in childhood, 4-8 D4Z4 repeats are associated 
with the classical form of FSHD, and 9-10 D4Z4 repeats with a milder disease [Lunt et al., 
1995b; Tawil et al., 1996; Ricci et al., 1999]. 
 In addition, D4Z4 alleles between 38-45 kb in size (9-11 D4Z4 repeats) have been described 
both in normal and affected individuals and are considered as borderline [Butz et al., 2003; 
Vitelli et al., 1999].   
 
3 MOLECULAR BASIS OF FSHD: PATHOGENETIC HYPOTHESIS 
 
The D4Z4 units are members of a large family of 3.3 kb tandem repeat loci that are located 
on the short arm of the acrocentric chromosomes, the pericentromeric regions (especially on 
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chromosome 1), and the telomeric regions of the long arms of chromosomes 4 and 10 
[Hewitt et al, 1994; Lyle et al, 1995].  
The organization of the D4Z4 repeat is rather unusual (Figure 3), in particular the presence of 
two homeobox sequences within the same open reading frame.  Homeobox genes, encoding 
homeodomain transcription factors, often play important roles in embryonic development. 
 
3.1 The role of DUX4 gene 
Each D4Z4 unit contains a putative promoter and a single open redaing frame (ORF) 
encoding a putative double homeobox gene, named DUX4 (figure 4)[Gabriels et al, 1999; 
Hewitt et al, 1994; Lyle et al, 1995]. Homeodomain proteins are important for many early 
and late developmental processes. Thus, DUX4 is considered a strong candidate for FSHD 
pathogenesis. It was hypothesized that partial deletion of the D4Z4 repeat array resulted in 
destabilization of the D4Z4 heterochromatin and in the inappropriate upregulation of DUX4 
[Hewitt et al, 1994; Gabriels et al, 1999]. DUX4 overexpression may induce cell death by 
apoptosis, induce caspase 3/7 activation and alter emerin distribution at the nuclear envelope. 
In addition, DUX4 overexpression may activate PITX1 (paired-like homeodomain 
transcription factor 1), as was determined for both a reporter gene fused to the Pitx1 promoter 
and the endogenous Pitx1 gene. Interestingly, upregulation of the PITX1 protein was also 
observed in muscle biopsies of patients with FSHD [Kowaljow et al, 2007; Dixit et al, 2007]. 
Nevertheless, for a long time, the functionality of the DUX4 gene was questioned, because of 
lack of introns and polyadenylation signals and absence of evidence for in vivo transcription 
[Hewitt et al, 1994; Gabriels et al, 1999; Winokur et al, 2003; Osborne et al, 2007; Alexiadis 
et al, 2007]. Instead, in the following years, D4Z4 homologues have been identified in 
several mammalian species and it was established that the DUX4 open reading frame (ORF) 
shows evolutionary conservation, disputing the non-functionality of DUX4 and suggesting a 
 
Figure 3: Schematic representation of the structure and the organization of the D4Z4 repeats. Each D4Z4 
unit has LSau motifs, the hhspm3 motif and two homeobox sequences. 	
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coding role, possibly during development. However, the study by Lemmers and coworkers 
[Lemmers et al. 2010] has suggested a new developmental model for the disease, reporting 
the requirement of DUX4 polyadenylation site for develop FSHD. The distal end of the 
repeat array and flanking pLAM1 sequences, which contains a poly(A) signal that 
presumably stabilizes this transcript, are thought to be crucially important for the 
development of FSHD.  
More detailed analysis of DUX4 expression shows that the DUX4 pre-mRNA can be 
alternatively spliced and it has been suggested that the FSHD muscle expresses a different 
splice form of DUX4 mRNA compared to control muscle [Snider et al, 2010], However, 
Jones and coworkers [Jones et al., 2012] observed the DUX4 mRNA and protein expression 
also in muscle biopsies and myogenic cells from genetically unaffected relatives of the FSHD 
patients Recently, transgenic mouse models carrying human genomic constructs with the 
FSHD subtelomeric region permissive for somatic DUX4 expression were generated [Krom 
et al, 2013]. Data suggest that these mice maintain the transcriptional profile of the DUX4 
retrogene as observed in FSHD patients and controls. However they do not show an obvious 
muscle pathological phenotype. Therefore the role of DUX4 in muscle disease still needs to 
be clarified. 
 
 
 
Figure 4: Localization of the DUX4 gene within each D4Z4 unit. On the permissive chromosomes the last 
copy of the DUX4 gene spices to the third region immediately flanking and stabilizing the transcript owing to 
the presence of the poly(A) signal (PAS). 
 
 
 
3.2 Expression of proximal genes controlled by D4Z4 
Although it is thought that deletions of D4Z4 are causally related to FSHD, it is not clear 
how this triggers the disease. It has long been speculated that such deletions may alter the 
expression of genes located within or nearby the repeats (figure 5). 
poly A 
DUX4 DUX4 DUX4 
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The region immediately proximal to the D4Z4 repeats harbors a number of candidate genes. 
This FSHD locus includes:  
i) FSHD-related gene 1 (FRG1), which encodes a nucleolar protein involved in 
RNA biogenesis [van Deutekom et al., 1996a; van Koningsbruggen et al., 2007; 
Bodega et al., 2009].  
ii) FSHD-related gene 2 (FRG2), a predicted transcript with no significant homology 
to any known protein [Rijkers T et al, 2004];  
iii) adenine nucleotide transporter 1 gene (ANT1), a gene involved in apoptosis, lying 
more distally from the 4qter (5.8 Mb) [Doerner et al., 1997].  
The overexpression of FRG1, FRG2, and ANT1 has been found in some muscles affected by 
FSHD [Gabellini et al., 2002; Laoudj-Chenivesse et al., 2005]. It has been shown that a 
transcriptional repressor complex binds D4Z4 unit, so it has been supposed that D4Z4 
deletion would trigger the gene overexpression as result of the lack of repression. Gabellini 
and coworkers, in 2002, found that, in FSHD muscle, 4q35 genes located upstream of D4Z4 
resulted inappropriately overexpressed. In particular, it was shown that an element within 
D4Z4 specifically bound a multiprotein complex consisting of YY1, HMGB2 and nucleolin 
proteins [Ginisty et al., 1999]. This multiprotein complex bound D4Z4 in vitro and  in vivo 
and mediated transcriptional repression of 4q35 genes. The authors hypothesized that 
deletion of repeated elements in the sub-telomeric region of 4q might act on neighboring 
genes by derepressing their transcription and thus starting a cascade of events which 
ultimately lead to FSHD, also explaining the autosomal dominant transmission. This 
hypothesis results also consistent with the observation that haploinsufficiency of distal 4q 
does not cause FSHD [Tupler et al., 1996]. Interestingly, the extent of 4q35 gene 
overexpression in FSHD skeletal muscle resulted inversely related to the number of D4Z4 
repeats, suggesting a direct correlation with disease severity. Moreover, the observation that 
4q35 gene overexpression is muscle specific could explain the muscular phenotype observed 
in the disease. Finally, the stochastic variation in gene expression in muscle cells may be 
responsible of the asymmetric muscle involvement and of the great clinical variability 
reported between and within families [Tupler and Gabellini, 2004]. 
Consistently with this hypothesis, interesting data come from the work of Gabellini and 
coworkers in 2006. In this study, a transgenic mice selectively overexpressing in skeletal 
muscle the 4q35 FRG1, FRG2 or ANT1 genes was generated. The authors found that FRG1 
transgenic mice developed a muscular dystrophy; by contrast, FRG2 and ANT1 transgenic 
mice resulted normal. The degree of mice muscle impairment appeared correlated with 
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transgene expression levels:  in particular, FRG1-low mice showed no evidence of kyphosis, 
whereas FRG1-intermediate and FRG1-high mice exhibited mild and severe kyphosis 
respectively, due to muscle degeneration. Skeletal muscle from FRG1 mice showed 
histological and ultrastructural dystrophic features characterized by the increase of fibers size 
variability, necrosis, nuclear centralizations and connective tissue. In the same study, the 
authors also found that in muscle cells from FRG1 transgenic mice and from FSHD patients, 
specific pre-mRNAs, such as fast skeletal muscle troponin T (Tnnt3) and myotubularin 
related protein 1 (Mtmr1), underwent aberrant alternative splicing [Gabellini et al 2006]. 
These genes resulted aberrantly spliced also in myotonic dystrophy patients and animal 
models [Buj-Bello et al., 2002; Kanadia et al., 2003], but not in muscle cell cultures derived 
from patients with Duchenne muscular dystrophy and congenital merosin deficient muscular 
dystrophy 1A [Gabellini et al., 2006]. Nevertheless, several follow-up studies could not 
reproduce the transcriptionally up-regulation of FRG1, FRG2 and ANT1 in FSHD muscle 
[Winokur et al., 2003; Celegato et al., 2006; Osborne et al., 2007]. The use of different 
techniques and different sources of RNA may partly explain this lack of reproducibility [de 
Greef et al., 2008]. 
Additional genes located at 4q35 were found to be transcriptionally upregulated in FSHD 
muscle. FAT1 gene is located 3.6 Mb from the D4Z4 repeat array on 4q35. FAT1, 
protocadherin gene in mouse is required in migrating muscle precursors and altered muscle 
shapes caused by Fat1 mutations are predictive of early onset defects in muscle integrity in 
adult mutants. The topography of muscle abnormalities caused by Fat1 loss-of-function 
resembles that of human patients with FSHD. Muscle-specific reduction of FAT1 expression 
and promoter silencing was observed in rare cases of biopsies from foetuses with a prenatal 
diagnosis of FSHD1 [Caruso et al, 2013]. 
 
 
Figure 5: Schematic representation of 4q35 showing physical distances between the genes (Gabellini et al., 
2002). 
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4 CLINICAL COMPLEXITY  
In contrast with the expected course for a classical autosomal dominant Mendelian disorder, 
since the first observations of FSHD families it was possible to establish that the chronology 
of disease progression is unpredictable, and disease expressivity ranges from subjects with 
very mild muscles weakness, almost unaware of being affected, to wheelchair-dependent 
patients [Ricci et al., 2014]. 
4.1 Atypical phenotypes associated with D4Z4 reduced alleles 
In the past 20 years, assessment of the D4Z4 array size as diagnostic test for FSHD has led to 
the identification of phenotypes that differs at various degrees from the original description 
of disease made by Landouzy-Dejerine. This has provoked a trend towards the expansion of 
the clinical pattern associated with D4Z4 reduced allele. Several subtypes of FSHD with 
atypical clinical presentation have been described. 
For example, in 2000 van der Kooi and coworkers described six sporadic cases that did not 
meet most of the diagnostic criteria defined in 1991 but the patients were diagnosed as FSHD 
because they carried a DRA (range 26 to 38 kb) on 4q. The foot drop was the predominant 
clinical feature found in three patients; in three others, inability to walk on toes, shoulder 
pain, and pelvic limb weakness with difficulty in walking were reported, respectively. None 
of them had facial weakness and only one complained of shoulder weakness. Interestingly, 
none had a positive family history [van der Kooi et al. 2000]. 
In the same year, Felice and coworkers described 10 patients out of 14, with facial-sparing 
scapular myopathy associated with DRA (range 20 to 39 kb). Except for the absence of facial 
weakness, most patients had clinical and laboratory features otherwise consistent with FSHD. 
Five patients referred also a positive family history of similar weakness, although DNA 
analysis was not performed on other family members [Felice et al., 2000]. 
Felice and Moore in 2001 also described four patients, each harboring DRA (range 25 to 34 
kb), who presented with atypical phenotypes including facial-sparing scapular myopathy, 
limb-girdle muscular dystrophy (LGMD) distal myopathy and asymmetric brachial 
weakness. Only the first two patients had undergone muscle biopsies, which showed 
unspecific dystrophic features. None of these patients underwent to other molecular 
investigations for differential diagnosis. Interestingly, the patient with LGMD phenotype and 
asymmetric brachial weakness did not report a positive family history for neuromuscular 
diseases. In this work, the authors concluded that the availability of the DNA test, considered 
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as highly sensible and specific, allowed to establish definitively the diagnosis without the 
need for the more invasive and less specific muscle biopsy [Felice and Moore in 2001].  
Krasnianski and coworkers in 2003 described three patients from a single family (father and 
two sons) in which a 23 kb DRA segregated. They showed signs consistent of typical FSHD 
associated with chronic progressive external ophthalmoplegia. The oculomotor impairment 
was reported as the initial manifestation of disease starting from infancy. The muscle biopsy 
of the father and one child demonstrated prominent myopathic changes without ragged red 
fibers or histopathological features of other neuromuscular diseases. The absence of single or 
multiple deletions of mitochondrial DNA apparently excluded a coincidental diagnosis of 
Chronic Progressive External Ophthalmoplegia (CPEO) of mitochondrial origin. On the other 
hand, the classic FSHD distribution of the muscle weakness had been never described in 
patients with CPEO. The possibility of oculopharyngeal muscular dystrophy was not 
investigated [Krasnianski et al. 2003]. In the same paper, the authors further described other 
two familial cases and one sporadic case with facial-sparing FSHD syndrome associated with 
D4Z4 reduced allele (34 and 30 kb allele, respectively) [Krasnianski et al., 2003]. 
Cardiac involvement, including hypertrophic cardiomyopathy, conduction defects and 
arrhythmia, has been reported in subjects carrying a DRA by several reports [Emmrich et al., 
2005; Tsuji et al., 2009], although the European Expert Group on FSHD in 1991, that defined 
the Diagnostic Criteria for FSHD in pre-molecular era [Padberg et al., 1991], defined that 
“cardiomyopathy is not part of the disease” and “when present it suggests an alternative 
diagnosis”. 
Reilich et al. described five unrelated cases carrying DRA whose biopsies showed signs of 
vacuolar myopathy with rimmed vacuoles. The atypical clinical features included a form of 
LGMD phenotype with facial-sparing, a form of distal and proximal weakness, which was 
associated with dysphagia in one patient and a form of a prevalent asymmetric lower limb 
distal weakness. Scapular winging or facial weakness was also reported, suggesting the 
possibility of an overlapping FSHD syndrome. In these cases the family history was negative 
for neuromuscular disorders or motor impairment, although molecular analysis was not 
performed in other family members. Only in one family the DNA testing revealed the same 
DRA (size 35 kb) in the mother and two sisters of the proband affected by distal weakness; 
these relatives showed a mild facial involvement at clinical examination. The five muscle 
biopsies of the above unrelated cases showed a pattern of degenerative myopathy with 
rimmed vacuoles and inflammatory infiltrates. Immunohistochemistry did not detect 
abnormal desmin, myotilin or alphabeta-crystallin deposits, excluding the diagnosis of 
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myofibrillar myopathies. Electron microscopy revealed autophagic vacuoles containing 
myelin-like material and filamentous nuclear inclusions. Interestingly, MRI imaging did not 
reveal the lower limb muscle involvement typical of FSHD [Reilich et al.; 2010]. 
Another several atypical phenotype associated with DRA is the Bent Spine Syndrome, a 
clinical condition characterized by a stooped posture in the standing position, which is 
exaggerated in walking or in exercise and disappears in the supine position, sometimes 
associated with a dropped head. The first reported case [Umapathi et al., 2002] was a 59-
years-old woman with a family history of FSHD, presenting with an overlapping condition 
with camptocormia, scapular winging and mild facial and proximal weakness. Kottlors et al. 
described the case of a 65-years-old man complaining of low back pain and progressive bent 
spine syndrome, since the age of 60, carrying a 31 kb DRA. The patient recalled that his 
mother had a similar posture that began at age of 80. The genetic analysis performed on the 
available family members revealed the presence of DRA in the two daughters, who showed 
signs of myopathic facies. In one of them slight weakness of foot extensors was observed. 
Nonetheless, none in the family presented a typical FHSD phenotype	[Kottlors et al., 2010]. 
Jordan and coworkers [2011] reported six sporadic cases carrying a DRA (range 21-34 kb) 
with prevalent axial weakness. All patients referred late disease onset in fourth-sixth decades. 
Muscle MRI imaging revealed that in all six patients the most severely affected muscles were 
the paraspinal of thoracic and lumbar tract together with hamstrings	[Jordan et al.; 2011].  
Some researchers think that the extensive use of genetic analysis has expanded the clinical 
and morphological spectrum of FSHD, and many consider the detection of DRA in a patient 
sufficient to diagnose FSHD. Interestingly, the atypical phenotypic cases are often sporadic. 
It may thus be supposed that in these cases the shorter D4Z4 fragment is not per se sufficient 
to trigger myopathy. Indeed the wide heterogeneity associated with alterations on 
chromosome 4q35 can suggest that other factors/pathologic conditions influence and 
modulate the disease expression, such as epigenetic or environmental factors. It may 
plausible that other genetic and/or environmental factors may participate in the onset of a 
myopathy that might present clinical features overlapping with FSHD. On the other hand, it 
must also be considered the possibility that other myopathies might have been misdiagnosed 
because of the random finding of a DRA in the affected subject.  
4.2 Several reports of “double trouble” conditions in FSHD families 
In FSHD, more than in other neuromuscular disorders, several patients affected by “double 
trouble” conditions are described. In these patients the D4Z4 reduced allele is associated with 
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a well-known pathogenic mutation of other genes, causing complex and overlapping 
phenotypes. In particular, patients with mitochondrial myopathy/FSHD [Filosto et al., 2008], 
Becker dystrophy/FSHD [Rudnik-Schöneborn et al., 2008], Duchenne dystrophy/FSHD 
[Lecky et al., 1991; Korngut et al., 2008], Leber’s hereditary optic neuropathy/FSHD 
[Chuenkongkaew et al., 2005], LGMD1C with rippling disease/FSHD [Ricci et al., 2012], 
myotonic dystrophy type 1/FSHD [Masciullo et al., 2013] were reported suggesting the 
possibility of a synergistic effect of those simultaneous mutations in reaching and in 
modulating the clinical expression.  
4.3 Penetrance of the disease in carriers of D4Z4 reduced allele 
In pre-molecular era, the first observations performed on large families with clinical 
diagnosis of FSHD suggested an almost complete penetrance of the disease. However, since 
the advent of molecular diagnosis for FSHD, subjects carrying DRA without signs of disease 
have been reported [De Greef et al, 2010], challenging the notion that DRA alone can cause 
nearly full disease penetrance.  
In a study on 52 Brazilian families with DRA smaller than 35 kb [Zatz et al., 1998], the 
estimated penetrance for FSHD allele was found to be 85% for patients until age 30. 
Furthermore, when the authors considered the sexes separately, the estimated penetrance of 
the FSHD allele was significantly greater for males (95%) than for females (69%). 
Interestingly, among 27 families with at least two clinically affected patients it was observed 
that in 21 families the pattern of inheritance was autosomal dominant (4 of them with 
incomplete penetrance). Surprisingly, in 3 pedigrees the pattern of inheritance was 
compatible with the presence of an autosomal recessive trait since there were at least two 
affected sibs born from asymptomatic parents. These observations suggested that FSHD 
phenotypes may result from distinct types of mutations in different families. 
A study conducted on Italian families [Ricci et al., 1999] reported 7 subjects, aged 20 to 69 
years, with DRA between 21 and 37 kb (4-8 units), without symptoms or signs of FSHD, 
who were classified as non-penetrant carriers. In this study, unaffected individuals were not 
observed in families with DRA smaller than 20 kb. 
A retrospective analysis conducted on 85 Japanese patients with FSHD and both their 
parents, documented parents with DRA who had no clinical symptoms, confirming an 
estimated low penetrance of  59% (excluding somatic mosaicism) [Goto et al., 2004]. 
Tonini and coworkers in 2004 analyzing 238 subjects with DRA <35 kb from 106 unrelated 
families, observed that about 20% of individuals related to FSHD patients who carried a 
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DRA remained asymptomatic or were minimally affected with a significantly higher 
proportion of females than males; asymptomatic carriers were found in about 30% of the 
families [Tonini et al. 2004]. 
More recently, Sakellariou and coworkers [Sakellariou et al., 2012] reported clinical and 
genetic analysis of 133 individuals carrying DRA (71 probands and 62 relatives) from 71 
unrelated Greek families, revealing a high percentage (almost 50%) of asymptomatic 
relatives older than 30 years and carrying DRA. The percentage of unaffected carriers was 
also lower in males than in females (29% vs 71%). It is also noteworthy that 16 among the 38 
multiple-case families (42%) were found to have at least one symptom-free individual, with a 
greater proportion of asymptomatic or minimally affected gene carriers concentrating in 
some pedigrees, as previously observed by Tonini and coworkers [Tonini et al., 2004]. A 
statistically significant association between the genders and the clinical manifestation of the 
disease was also observed: among the females the percentage of symptomatic patients was 
found to be 66.7% whereas among the males it was 86.6%. 
4.4 FSHD without D4Z4 repeats contraction on chromosome 4q35 (FSHD2) 
The cohort of patients, termed “FSHD2” display D4Z4 alleles of normal size on both 4q 
alleles and they fulfill clinical diagnostic criteria for FSHD [Tawil et al, 2010], resulting 
clinically indistinguishable from FSHD patients carrying D4Z4 reduced allele (also defined 
FSHD1).  
In 2010 de Greef and coworkers have performed a cross-sectional study on 33 patients with 
FSHD2 from 27 families, the largest cohort described to date. The clinical presentation of 
FSHD2 patients appeared identical to the FSHD1. Out of 33 FSHD2 patients 20 (61%) were 
male. The average age at symptom onset was 26 years (range 0–60), which is almost 10 years 
later than in FSHD1. The reported initial symptom was scapular weakness in 61%, foot 
dorsiflexor weakness in 27%, facial weakness in 10%, and hip girdle weakness in 3%. A 
gender differences in disease severity in FSHD2 was not observed. The most interesting 
difference between FSHD1 and FSHD2 is the inheritance mode. In fact, the analysis showed 
that the majority (20/33, 67%) of cases was sporadic, 11 were familial, and 2 had an 
uncertain inheritance pattern, suggesting that the familial to sporadic ratio in FSHD2 is 
inverse to the ratio in FSHD1. Of the familial cases, 3 resulted dominant in inheritance 
(parent-child pairs) and 2 seemed recessive in inheritance (sibling pairs). It has been 
suggested that epigenetic and molecular mechanisms, also supposed to be pathogenic in 
FSHD associated with D4Z4 repeat contraction, are involved. 
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5 GENETIC COMPLEXITY  
 
5.1 Specific haplotypes associated with D4Z4 reduced alleles 
Since there are individuals with reduced D4Z4 alleles that do not have clinical signs of 
FSHD, it has been proposed that additional DNA sequences flanking the D4Z4 repeat array 
are necessary for disease development. In 2002 a polymorphic segment of 10 kb directly 
distal to D4Z4 and presenting in two allelic forms, 4qA and 4qB, was identified [van Geel et 
al, 2002](Figure 6). Although, both alleles are equally common in the general population, it 
was reported that FSHD is solely associated with the 4qA allele. Lemmers and coworkers, in 
2002, analyzed 80 healthy controls and 80 unrelated individuals with FSHD for the presence 
of 4qA and 4qB alleles. In the controls they observed almost equal frequencies of 4qA and 
4qB alleles (42% and 58% respectively) on chromosome 4, but only alleles of the 4qA type 
on chromosome 10. By contrast, in the 80 unrelated individuals with FSHD (44 de novo 
cases and 36 unrelated familial cases) they detected D4Z4 reduced alleles exclusively in 
chromosomes 4 bearing the 4qA allele, and never in those with the 4qB allele [Lemmers et 
al, 2002]. Subsequently, [Lemmers et al, 2004a] described three families with FSHD in 
which each proband of the family carried two FSHD-sized alleles and was heterozygous for 
the 4qA/4qB polymorphism. Segregation analysis demonstrated that FSHD-sized 4qB alleles 
were not associated with disease, since these were present in unaffected family members. 
Thus, the authors supposed that, in addition to a contraction of D4Z4, other cis-acting 
elements on 4qA might be necessary for the development of FSHD. Alternatively, they 
proposed that elements present at 4qB sub-telomeres might prevent pathogenesis of FSHD. 
In 2007, the identification of additional sequence variations in a relatively stable Simple 
Sequence Length Polymorphisms (SSLP) proximal to the D4Z4 repeat were identified in the 
FSHD locus [Lemmers et al, 2007]. On the basis of the proximal SSLP, it was possible to 
distingush at least 17 genetically distinct sub-telomeric variants of chromosome 4 and 8 sub-
telomeric variants of chromosome 10. It was supposed that only D4Z4 contractions in three 
specific sub-telomeric variants on chromosome 4, the common 4A161 and the rarer 4A159 
and 4A168, are responsible for developing FSHD. Contractions in other 4q sub-telomeres 
were not associated with the disease. The authors presented the pedigrees of two FSHD 
families in which two different D4Z4 reduced allele segregate, reporting that subjects 
carrying the D4Z4 reduced allele with non-permissive 4qA166 haplotype did not manifest 
signs of disease.  
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Finally, it has been suggested that FSHD patients carry specific single nucleotide 
polymorphism (SNP) ATTAAA in the chromosomal region distal to the last D4Z4 repeat in 
the pLAM sequence of the 4qA alleles, and this SNP provides a PolyAdenylation Signal 
(PAS) [Lemmers et al,  2010]. Thus, the specific molecular signature, named 
4A(159,161,168)PAS, has been proposed to define genetic background responsible for FSHD 
pathogenesis (Figure 7). This specific background is characterized by (1) reduction of D4Z4 
elements associated with (2) the 4qA (161/159/168) haplotype (3) and a single nucleotide 
polymorphism, ATTAAA, in the pLAM sequence (figure 7).  
	
Figure 6: Schematic representation of 4qA/4qB polymorphism.		
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5.2 Epigenetics in FSHD 
The D4Z4 repeat is GC-rich and contains sequences often residing in heterochromatic 
domains of the genome [Lyle et al., 1995]. DNA methylation analysis and studies of histone 
modifications has supported the hypothesis that the reduction of D4Z4 repeat, that normally 
is in a relatively closed chromatin configuration, causes a more open chromatin configuration 
facilitating the transcriptional activity of the repeat and possibly affecting the processing of 
the different D4Z4 transcripts [Jiang et al., 2003; van Overveld et al., 2003; Zeng et al., 
2009]. Chromatin immunoprecipitation studies showed that the D4Z4 repeat is normally 
occupied by both transcriptionally repressive as well as permissive histone modifications. In 
FSHD patient chromosomes, it is observed a relative loss of repressive histone modifications; 
these changes in chromatin structure are restricted to the D4Z4 repeat and do not seem to 
spread proximally. Chromatin immunoprecipitation studies also identified other chromatin 
factors that were lost or gained, including HP1γ, the cohesin complex, YY1 (lost) and CTCF 
(gained) at D4Z4 of disease alleles [Gabellini et al., 2002; Zeng et al., 2009; Ottaviani et al., 
2009].  
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At present, the epigenetic model in FSHD is based on the assumption that methylation or 
histone modifications, as additional levels of complexity, can help interpreting the complex 
correlation between genotype and phenotype in FSHD [De Greef et al., 2009].. Because the 
methylation status of CpG sites could play a critical role in chromatin configuration, D4Z4 
methylation status was investigated in FSHD patients. The first study investigated 
methylation at SmaI, MluI, SacII, and EagI methylation-sensitive restriction sites in blood 
and skeletal muscle samples of FSHD and normal subjects [Tsien et al, 2001]. The authors 
observed that D4Z4 was found highly methylated in both normal and FSHD lymphoblasts, as 
well as in somatic tissues, including skeletal muscle. However, the study did not discriminate 
methylation status of the D4Z4 repeat array at chromosome 4 and chromosome 10. 
Subsequently, DNA methylation was examined at two methylation-sensitive restriction sites, 
BsaAI and FseI, in the most proximal unit of D4Z4 array at 4q35, which was considered 
representative for the entire array [van Overveld et al, 2003]. Through this approach the 
D4Z4 methylation level can be assessed on both chromosomes 4, excluding chromosome 10. 
The limitation of this test is due to the possibility to analyze D4Z4 methylation status only in 
individuals carrying standard allele constitution of 4-type repeat units on chromosome 4 and 
10-type on chromosome 10 (subjects termed disomic), or on individuals carrying one array of 
10-type repeat units at normal sized chromosome 4 (subjects termed monosomic). The 
authors observed normal level of methylation in healthy subjects, significant 
hypomethylation at both methylation sensitive sites in FSHD1 patients and similar level of 
hypomethylation in their non-penetrant relatives, carrying the same D4Z4 reduced allele. 
Interestingly, in FSHD2 patients the level of D4Z4 methylation on both chromosomes 4 was 
strongly decreased, while it was equivalent among unrelated individuals affected with 
muscular dystrophy different from FSHD and healthy controls [van Overveld, 2003]. Further 
investigations of the methylation status were performed by van Overveld and coworkers in 
2005 in 21 monosomic FSHD1 patients and 19 monosomic healthy controls [van Overveld et 
al., 2005]. The study showed that patients with DRA between 10 and 19 kb (1-3 D4Z4 units) 
showed very low DNA methylation levels, whereas FSHD patients with DRA with 4-6 D4Z4 
units, showed inter-individual variation in both clinical severity and D4Z4 hypomethylation.  
Using bisulfite sequencing of DNA from blood and myoblast cells, methylation levels at 74 
CpG sites across 3 disparate regions within D4Z4 were measured in FSHD2 patients and 
controls by Hartweck and coworkers in 2013 [Hartweck et al., 2013]. The authors found that 
rates of demethylation caused by FSHD2 are not consistent across D4Z4. They identified a 
focal region of extreme demethylation within a 59 domain, which was named DR1. Other 
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D4Z4 regions, including the DUX4 ORF, were hypomethylated but to a much lesser extent. 
More recently, Jones and coworkers [2015] analyzed family cohorts for DNA methylation on 
the distal pathogenic 4q35 D4Z4 repeat on permissive A-type subtelomeres. They found 
DNA hypomethylation in FSHD1-affected subjects, hypermethylation in healthy controls, 
and distinctly intermediate levels of methylation in non manifesting subjects. 
An other assay that has been used in evaluating the level of DNA methylation is the 
immunoprecipitation of methylated DNA fragments (MeDIP) followed by quantitative PCR, 
alghout this approch is less direct and less sensitive [Gaillard et al., 2014]. To investigate the 
link between clinical signs of FSHD and DNA methylation, the authors explored 95 cases (37 
FSHD1, 29 asymptomatic individuals carrying a shortened D4Z4 array, 9 patients with 
FSHD2, and 20 controls) by implementing two approaches, the methylated DNA 
immunoprecipitation and the sodium bisulfite sequencing. Both methods revealed 
statistically significant differences between asymptomatic carriers or controls and individuals 
with clinical FSHD, especially in the proximal region of the repeat. Absence of clinical 
expression in asymptomatic carriers resulted associated with a level of methylation similar to 
controls. 
Collectively, in the last three years the partial loss of D4Z4 methylation in FSHD1 and 
FSHD2 has been demonstrated by Southern blot analysis using several methylation-sensitive 
restriction enzymes, by bisulfite sequencing and methylated DNA immunoprecipitation 
(MeDIP) analysis at D4Z4. These studies have shown that the different approaches revealed 
similar patterns of D4Z4 methylation, where D4Z4 hypomethylation in FSHD is universal 
across muscle, fibroblasts and peripheral blood mononuclear cells.  
5.3 SMCHD1 gene in FSHD1 and FSHD2 
In 2012 Lemmers and coworkers firstly identified mutations in SMCHD1 gene by performing 
whole-exome sequencing in 12 individuals from 6 unrelated FSHD2 families; all these 
subjects showed a methylation threshold <25%, on the basis of measurements following 
cleavage with the methylation-sensitive FseI endonuclease, in an assay that averaged the 
percentage of D4Z4 methylation on both alleles of chromosomes 4 and 10. The authors 
observed that individuals with FSHD2 inherited both the hypomethylation trait and the 
FSHD-permissive chromosome 4 haplotype with the DUX4 polyadenylation signal, 
suggesting that two independently segregating loci cause and determine the penetrance of 
FSHD2 (figure 8). They then confirmed heterozygous out-of-frame deletions, heterozygous 
splice-site mutations and heterozygous missense mutations in SMCHD1 in 15 out of 19 
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FSHD2 families (79%). Because heterozygous SMCHD1 mutations cosegregated with D4Z4 
hypomethylation in families with FSHD2 or occurred de novo in individuals with sporadic 
hypomethylation and FSHD2, the authors considered SMCHD1 haploinsufficiency to be a 
candidate disease mechanism, particularly because many of the mutations were predicted to 
affect production of the full-length protein [Lemmers et al., 2012]. The SMCHD1 gene on 
chromosome 18p consists of 48 exons and encodes for a protein containing a putative 
ATPase and hinge domain. SMCHD1 encodes a member of the structural maintenance of 
chromosomes (SMC) protein superfamily involved in chromatin repression of specific 
genomic regions including the D4Z4 units.  In mice, SMCHD1 has been shown to be 
involved in the establishment and maintenance of DNA methylation of a subset of CpG 
islands on the inactive X chromosome (Xi), of repetitive sequences, and of monoallelically 
expressed autosomal genes [Blewitt et al., 2005]. SMCHD1 binds to the D4Z4 repeat array in 
somatic cells, and reduced SMCHD1 binding to the D4Z4 repeat array has been reported in 
individuals with FSHD2. In SMCHD1 mutation carriers, all D4Z4 repeat arrays from 
chromosomes 4 and 10 are hypomethylated. Together, these data are consistent with a role 
for SMCHD1 keeping D4Z4 and DUX4 in a repressive chromatin structure in somatic tissue 
[Lemmers et al., 2015]. Although the reduced D4Z4 methylation in FSHD2 individuals was 
found in peripheral blood mononuclear cells (PBMCs), fibroblasts and myoblasts, the 
expression of DUX4 was, as in FSHD1, only observed in skeletal muscle biopsies and in 
differentiated myoblasts (12). In the recent work of Lemmers and coworkers [Lemmers et al., 
2015], the authors further investigated 41 families with one or more individuals with FSHD2 
that have not been analyzed for SMCHD1 mutations previously and, overall, they reported 
the results obtained on 60 FSHD2 families. All affected individuals from these families had a 
phenotype consistent with FSHD and a combined CpG methylation level on chromosomes 4 
and 10 D4Z4 that was below 25% of the defined threshold for FSHD2. In 51 of the 60 
families, they identified an SMCHD1 mutation. In total, they reported 83 carriers of an 
SMCHD1mutation with an average D4Z4 methylation of 12.1% and 45 unaffected relatives 
without mutation and with an average D4Z4 methylation of 46.8%. The authors also 
identified 9 families (15%) with a total of 17 affected individuals for which they did not find 
mutations in SMCHD1 despite an average D4Z4 DNA methylation of 16.5% [Lemmers et 
al., 2015]. In addition, Sacconi and coworkers hypothesized that SMCHD1 may act as a 
genetic modifier in FSHD Sacconi et al., 2013]. The authors describe three unrelated 
individuals with FSHD1 presenting an unusual high clinical severity based on their upper-
sized FSHD1 repeat array of nine units. Each of these individuals also carries a mutation in 
	 26	
the SMCHD1 gene. Familial carriers of the FSHD1 allele without the SMCHD1 mutation 
were only mildly affected, suggesting a modifier effect of the SMCHD1 mutation [Sacconi et 
al., 2013].  
5.4 The hypothetical unifying pathogenic model 
To date, the epigenetic model in FSHD speculates that in autosomal dominant FSHD1 D4Z4 
chromatin relaxation and DUX4 expression are caused by a contraction of the D4Z4 repeat 
array to a size of 1–10 units. In the uncommon form of FSHD (FSHD2), D4Z4 chromatin 
relaxation occurs in the absence of D4Z4 repeat array contraction. In FSHD1, chromatin 
relaxation and CpG hypomethylation are restricted to the contracted allele, whereas in 
FSHD2 chromatin relaxation and CpG hypomethylation occur at the D4Z4 repeat arrays of 
both copies of chromosome 4 and in the highly homologous repeat arrays on chromosome 10 
[van den Boogaard 2016; Daxinger et al., 2015]. The D4Z4 methylation is used as a measure 
of D4Z4 chromatin relaxation. In particular, it has been considered an informative measure of 
D4Z4 methylation by measuring the methylation of all D4Z4 arrays simultaneously at a 
unique methylation-sensitive restriction site (FseI) in the D4Z4 unit. It has been observed that 
D4Z4 methylation level at this site is repeat array size dependent. Moreover, the methylation 
level at this site is significantly lower in FSHD2 compared with both FSHD1 and controls, 
and a threshold of 25% was established for FSHD2. D4Z4 chromatin relaxation only results 
in stable DUX4 expression when the D4Z4 repeat array contraction occurs in cis with a 
polymorphic DUX4 polyadenylation signal (PAS) present on a FSHD-permissive 
chromosomal background (4A). A similar D4Z4 repeat array is located equally on the 
common chromosome 4B variant and on chromosome 10, but contractions of the array on 
these locations typically do not result in stable DUX4 expression and disease owing to the 
absence of the DUX4-PAS. DUX4 is a transcription factor normally expressed in the luminal 
cells of the testis, and its expression in muscle activates germline and early stem cell 
programs eventually resulting in muscle cell death. 
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Figure 8:Genetic basis of FSHD1 and FSHD2. CEN indicates the centromeric end and TEL indicates the 
telomeric end. Upon contraction the D4Z4 chromatin structure becomes derepressed (green) facilitating the 
expression of the DUX4 retrogene of which a copy is embedded within each unit. DUX4 (white boxes with open 
reading frame in black) within the D4Z4 unit does not have a polyadenylation signal (PAS), but, in somatic 
cells can make use of a polymorphic PAS immediately distal to the D4Z4 repeat present on 4qA but not on 4qB 
chromosomes. Thus, only on 4qA chromosomes, D4Z4 chromatin derepression leads to the production of 
DUX4 protein. SMCHD1 is a chromatin modifier that binds to the D4Z4 repeat to keep the D4Z4 chromatin 
structure in a repressed state in somatic cells. Individuals with a mutation in SMCHD1 (asterisk), in 
combination with a DUX4 polyadenylation signal, can express DUX4 in their muscles. This is called FSHD2. 
(Daxinger et al., 2015) 	
 
 
THE ITALIAN NATIONAL REGISTRY FOR FSHD 
 
The Italian National Registry has been developed since 2008 by Italian Clinical Network for 
FSHD. The FSHD Italian Network is composed by a diagnostic laboratory (Miogen lab) 
directed by Prof. Rossella Tupler at the Università di Modena e Reggio Emilia and fourteen 
Clinical Centers with expertise in diagnosis and management of neuromuscular disorders, 
distributed across all of Italy, from northern to southern regions. The neuromuscular Clinical 
Centers are the following: Department of Neurosciences, Reproductive Sciences and 
Odontostomatology “Federico II” University of Naples (Prof. Lucio Santoro), Department of 
Neurology, IRCCS Fondazione Ospedale Maggiore Policlinico, University of Milan (Prof. 
Maurizio Moggio) IRCCS Foundation, C. Besta Neurological Institute at Milan (Dr Lorenzo 
Maggi), Department of Neuroscience, University of Turin (Prof. Tiziana Mongini), 
Department of Neurosciences, University of Padova (Prof. Elena Pegoraro), IRCCS S. 
Camillo at Venice (Prof. Corrado Angelini), IRCCS “C.Modino” Foundation, University of 
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Pavia (Dr Angela Berardinelli), Department of Neurological Sciences and Vision, University 
of Verona (Dr. Giuliano Tomelleri), University Hospital "Spedali Civili” of Brescia (Dr. 
Massimiliano Filosto), Department of Clinical and Experimental Medicine, University of 
Pisa (Prof. Gabriele Siciliano), Department of Neurology, S. Andrea Hospital, "Sapienza" 
University of Rome (Prof. Giovanni Antonini), Center for Neuromuscular Disease, 
University "G. d'Annunzio" of Chieti (Dr. Antonio Di Muzio), Department of Neurosciences, 
Psychiatry and Anaesthesiology University of Messina (Prof. Carmelo Rodolico), ASL8 
University of Cagliari (Prof. Giovanni Marrosu). 
Starting from data collected since 2008 in Italian National Registry for FSHD the following 
studies are ongoing:  
i. classification FSHD patients and families in homogeneous sub-groups on the basis of 
phenotypic features;  
ii. research for modifier loci/new genes through whole exome sequencing and candidate 
gene approach.  
iii. investigation of the natural history of the disease through the prospective clinical 
evalution of DRA carriers;  
 
Since 2008, 2460 carriers of a DRA within 1-10 repeats from 1273 unrelated families have 
been recruited and clinically evaluated. In the Clinical Centers, the neurological examination 
has been also extended to all available FSHD family members, also addressing relatives to 
further diagnostic analysis. The Miogen laboratory have been providing molecular 
characterization of index cases and their family members. A specific software for data 
management has been designed. The dedicated website for data management, description of 
the project and participating groups are available on-line at www.fshd.it. 
 
From the article: “A standardized clinical evaluation of patients affected by 
facioscapulohumeral muscular dystrophy: the FSHD clinical score [Lamperti et al., 2010]” 
 
To define numerically the clinical severity of FSHD, we developed a protocol that quantifies 
muscle weakness by combining the functional evaluation of six muscle groups affected in 
this disease. To validate reproducibility of the protocol, 69 patients were recruited. Each 
patient was evaluated by at least five neurologists, and an FSHD severity score was given by 
each examiner. The degree of agreement among clinicians’ evaluations was measured by 
kappa-statistics. The clinical form consists of three parts, named A, B, and C, that examine 
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three aspects of the disease and have been designed to facilitate accurate studies of 
molecularly defined FSHD subjects.  
- Part A investigates the patient’s clinical history, focusing on medical conditions and 
particular habits.  
- Part B evaluates the patient’s disability.  
- Part C assesses muscle segmental involvement by using the Medical Research 
Council (MRC) scale.  
The evaluation procedure allows to assess the strength and the function of muscular groups 
belonging to I) face (score from 0 to 2); II) shoulder girdle (score from 0 to 3); III) upper 
limbs (score from 0 to 2); IV) distal legs (0-2); V) pelvic girdle (score from 0 to 5) VI) 
abdominal muscles (0-1). The total score can range from 0, when no signs of muscle 
weakness are present, to 15, when all muscle groups tested are severely impaired (Figure 1). 
The FSHD clinical form and the FSHD evaluation scale, as well as a visual guide, are 
available online at www.fshd.it. English and Italian versions of the two forms can be 
downloaded from the website. To date, the Italian Network for FSHD successfully use the 
FSHD clinical score as a tool in genotype/phenotype correlation and genetic counseling.  
 
FSHD Evaluation Scale [Lamperti et al., 2010] 
 
I - Facial weakness 
0 - no weakness 
1 - moderate weakness; partial ability to do at least one of the following tasks: 
- to close eyes 
- to protrude lips 
- to put out cheeks 
2 - severe weakness; unable to do at least one of the following tasks: 
- to close eyes 
- to protrude lips 
- to put out cheeks 
 
II - Scapular girdle involvement 
0 - no involvement 
1 - mild involvement with no limitation of arm abduction 
2 - arm abduction  > 45 
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3 - arm abduction  ≤ 45 
 
III - Upper limbs involvement * 
0 - no involvement 
1 - at least two muscles impaired with MRC >3 
2 - at least two muscles impaired with MRC ≤ 3 
*The following 4 muscles are assessed on each side: 1.triceps; 2. biceps; 3. Common finger extensors 
and wrist extensors; 4. long finger flexors and wrist flexors. Only the weaker muscles will be 
considered for evaluation. 
 
IV - Legs involvement 
The ability to walk on tiptoes and heels will be assessed on each side: 
0 - no involvement 
1 - unable to walk on tiptoes or heels (only one task impaired) 
2 - unable to walk on tiptoes and heels (two tasks impaired) 
 
V - Pelvic girdle involvement 
0 - no involvement 
1 - able to walk and to climb stairs without support but abnormally/ because of 
posterior leg muscle hypotrophy 
2 - able to walk unaided, to climb stairs or to stand up from a chair with support 
3 - able to walk unaided but unable to stand up from a chair or to climb stairs without 
support/ more than 12 seconds 
4 - able to walk with support 
5 - wheelchair bound 
 
VI - Abdominal muscle involvement 
0 - no involvement 
1 - presence of Beevor's sign 
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SECTION 2: challenges in diagnosis of FSHD 
 
From the article: “Large scale population analysis challenges the current criteria for the 
molecular diagnosis of fascioscapulohumeral muscular dystrophy” 
Scionti I, Greco F, Ricci G, Govi M, Arashiro P, Vercelli L, Berardinelli A, Angelini C, Antonini G, Cao M, Di Muzio A, Moggio M, 
Morandi L, Ricci E, Rodolico C, Ruggiero L, Santoro L, Siciliano G, Tomelleri G, Trevisan CP, Galluzzi G, Wright W, Zatz M, Tupler R. 
[Am J Hum Genet. 2012] 
  
The reduction in the number of D4Z4 elements combined with the 4A(159/161/168)PAS 
haplotype (which provides the possibility of expressing DUX4) has been used as the genetic 
signature uniquely associated with FSHD. However, the frequency of compound 
heterozygotes in patients with FSHD suggested that the frequency of D4Z4-reduced 24-35 kb 
alleles associated with the 4A161PAS in the Italian population would be >1% [Scionti et al., 
2012]. In order to confirm the high frequency of this signature in the normal population and 
reevaluate the allele distribution in FSHD patients, it was performed a systematic unbiased 
clinical and molecular study of 801 normal control subjects from Italy and Brazil and 253 
FSHD probands from the INRF. Control subjects were recruited through advertisements from 
the Italian populations and resulted equally distributed among Northern, Central and 
Southern regions. DNA from Brazilian controls was provided by Department of Genetics and 
Evolutive Biology, Institute of Biosciences, University of São Paulo. It was observed that 3% 
(25 of 801) of normal controls carried D4Z4 alleles of reduced size and 11 (~1.3%) had the 
supposedly pathogenic 4A161PAS haplotype.  The age of all these healthy carriers ranged 
between 40 and 78 years, an age in which FSHD is considered to be fully penetrant. Only 
127 FSHD probands carried the 4A161PAS haplotype associated with alleles having 1-8 
D4Z4 repeats. Among the remaining probands, 52 showed reduced alleles associated with the 
4A166PAS haplotype previously considered not to be “permissive” for FSHD disease, 13 
carried the 4A162PAS, 5 the 4A164PAS, 2 the 4A167PAS, 1 the 4A163PAS, and 3 of them 
carried reduced D4Z4 alleles with the 4qB polymorphism which lacks both the pLAM1 
region and the PAS. Collectively, these data suggested that SSLP allelic variants associated 
with D4Z4-reduced alleles differed from those previously reported [Lemmers et al., 2007]. 
The 4A168 “permissive” haplotype associated with FSHD was not found in the study.  
Interestingly, haplotypes considered not to be “permissive” for FSHD disease were frequent. 
In particular the 4A166PAS haplotype was reported associated with almost one quarter 
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(23.3%) of D4Z4 reduced alleles detected in FSHD probands. More importantly, 49 of 253 
FSHD probands (19%) carried alleles with more than 8 D4Z4 repeats and only 127 (50.1 %) 
showed D4Z4 reduced alleles associated with the 4A161PAS, the expected molecular 
signature for FSHD. Therefore, the study shows that the current genetic signature of FSHD is 
a common polymorphism and only half of FSHD probands carry this molecular signature. 
 
From the article: “Large scale genotype-phenotype analyses indicate that novel prognostic 
tools are required for families with facioscapulohumeral muscular dystrophy.” 
Ricci G, Scionti I, Sera F, Govi M, D'Amico R, Frambolli I, Mele F, Filosto M, Vercelli L, Ruggiero L, Berardinelli A, Angelini C, Antonini 
G, Bucci E, Cao M, Daolio J, Di Muzio A, Di Leo R, Galluzzi G, Iannaccone E, Maggi L, Maruotti V, Moggio M, Mongini T, Morandi L, 
Nikolic A, Pastorello E, Ricci E, Rodolico C, Santoro L, Servida M, Siciliano G, Tomelleri G, Tupler R. [Brain. 2013] 
 
Several studies conducted on FSHD families have described a high variability in clinical 
expression among and within FSHD families, as well as asymptomatic subjects carrying 
DRA, doubting the notion of an almost full penetrance of disease. Thus we considered it is 
important to establish the penetrance of disease in FSHD families carrying DRA and to 
ascertain previously reported rough and inverse correlation between the size of DRA and the 
age at onset and severity of disease expression.   
The selection process was conducted on 418 FSHD index cases carrying DRA with 1-8 
repeats (Figure 9). 
 
 
Figure 9: Preliminary selection of probands/families from the Italian National Registry for FSHD 
(INRF). 	
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We divided subjects in three groups: subjects carrying DRA with 1-3 D4Z4 repeats; 
subjects carrying DRA with 4-6 D4Z4 repeats; subjects carrying DRA with 7-8 D4Z4 repeats 
(Figure 10). 
The distribution of asymptomatic relatives was analyzed based on the size of DRA. 
Graphic 1 shows that 9.5% (4 out of 42) of all carriers of DRA with 1-3 repeats did not 
display motor impairment. This percentage increases among carriers of DRA with 4-6 and 7-
8 repeats (28.6% and 39.6% respectively).  
 
 
Figure 10: Selection of the cohort of probands and their relatives for genotype–phenotype correlation 
analysis. 	
 
Graphic 1: The distribution of asymptomatic DRA carriers in three groups.  	
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In addition we calculated the distribution of asymptomatic carriers based on the age at 
examination: subjects aged between 18-30, 31-55, 56-70 years, and subjects over 70 years of 
age. As shown in Table 1 asymptomatic DRA carriers were found in all classes up to 70 
years. In particular, almost one third of carriers of DRA with 4-6 and 7-8 repeats (27.6% and 
35.9%, respectively) were asymptomatic between 56 and 70 years of age.         
 
We tested whether the size of DRA correlates with age at onset and disease severity. Table 2 
shows that the mean age at onset is statistically lower among subjects carrying DRA with 1-3 
units (20.3 years) in comparison with those carrying DRA with 4-6 and 7-8 D4Z4 repeats 
(respectively 29.2 and 34.6 years) (p = 0.0002).  
 
Severity is also increased among carriers of DRA with 1-3 repeats. Indeed, as shown in 
Table 3, affected relatives carrying DRA with 1-3 repeats had a mean FSHD score of 7.2.  
	
Table 1: The percentage of asymptomatic DRA carriers in the group of 1-3, 4-6 and 6-8 DRA based at the 
age at onset. 	
	
Table 2: The age at onset in the group of 1-3, 4-6 and 7-8 DRA carriers. 
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Table 3: The mean FSHD score in the group of 1-3, 4-6 and 7-8 DRA carriers. 	
	
		
Graphic 2: The degree of motor impairment among relatives was also evaluated in association with 
D4Z4 allele size and age at examination. 		
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By contrast, individuals carrying DRA with 4-6 and 7-8 D4Z4 units had mean FSHD score of 
4.4 and 4.1 respectively. This association was statistically significant (p = 0.0006) and was 
obtained by using linear regression model adjusted for age at examination. 
The degree of motor impairment among relatives was also evaluated in association with 
D4Z4 allele size and age at examination. Graphic 2 shows that approximately 40% of 
relatives carrying DRA with 1-3 units are severely affected (FSHD score ≥7) by age 30. In 
contrast, no relatives carrying DRA with 4-8 units had a FSHD score higher than 6 in this age 
window. Figure 10 shows that between age 31-55 and 56-70 a high percentage (ranging 
between 32% and 37%) of relatives carrying DRA with 4-8 units were asymptomatic (FSHD 
score equal to zero) or displayed minimal signs of functional motor impairment (FSHD score 
1-2, ranging between 15% and 27%). 
Our large scale genotype-phenotype study [Ricci et al, 2013] revealed that FSHD penetrance 
in DRA carriers is not complete by age 20, as previously proposed [Tawil et al, 2010], as 
asymptomatic carriers in all the classes of ages up to 70 years were found. It was shown that 
DRAs with 4–8 repeats have no definitive prognostic value, and that other prognostic 
parameters, beside DRAs, should be considered. Instead, the risk of developing the motor 
impairment by age 50 in FSHD family members is higher (83–93%) in subjects carrying 
DRA with 1–3 repeats. Interestingly, in our cohort, 19 of 148 FSHD families (13%) in which 
a DRA with 4–8 units segregates presented affected subjects only in one generation. In these 
cases the lack of autosomal dominant inheritance should prompt us to consider whether the 
disease develops because of the presence of additional genetic defect(s).  
Collectively, the wide clinical variability among subjects carrying 4-8 D4Z4 repeats together 
with the high number of asymptomatic or minimally affected carriers suggests that additional 
factors, such as genetic, epigenetic and environmental factors, are involved in reaching the 
threshold of disease appearance and/or modifying the clinical outcome [Scionti et al, 2012]. 
Remarkably, the study shows a higher percentage of asymptomatic subjects between relatives 
with lower degree of relationship with proband, regardless age and D4Z4 size. The degree of 
kinship may influence the disease outcome, as result of genetic background “dispersion”, 
suggesting a more complex mode of inheritance of FSHD. 
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From the article: “Clinical expression of facioscapulohumeral muscular dystrophy in 
carriers of 1-3 D4Z4 reduced alleles: experience of the FSHD Italian National Registry.” 
Nikolic A, Ricci G, Sera F, Bucci E, Govi M, Mele F, Rossi M, Ruggiero L, Vercelli L, Ravaglia S, Brisca G, Fiorillo C, Villa L, Maggi L, 
Cao M, D'Amico MC, Siciliano G, Antonini G, Santoro L, Mongini T, Moggio M, Morandi L, Pegoraro E, Angelini C, Di Muzio A, 
Rodolico C, Tomelleri G, Grazia D'Angelo M, Bruno C, Berardinelli A, Tupler R. [BMJ Open. 2016 ] 
 
The alleles of extremely short sizes (1-3 D4Z4 repeats) were described to be associated with 
the most severe form of disease characterized by an early onset and rapid progression of 
muscle weakness [Jardine et al, 1994; Lunt et al, 1995; Ricci et al, 1999; Ricci et al, 2013]. 
Infantile FSHD has been subsequently described as a separate entity, defined by the onset of 
facial weakness by the age of 5 years and shoulder girdle weakness by the age of 10. A 
number of reports described cases carrying very short D4Z4 alleles with 1-2 repeats 
characterized by childhood onset, rapid progression of muscle weakness and extramuscular 
clinical features [Okinaga et al, 1997; Wang et al, 2012]. However several studies reported 
differences in clinical expression between subjects carrying shorter alleles, varying from very 
severe forms of disease and complex phenotypes starting in infancy [Okinaga et al, 1997; 
Dorobek et al, 2004] to milder form or asymptomatic carriers [Tupler et al., 1998; 
Sakellariou et al, 2012]. By revising the literature, we found that the severe cases not all had 
a childhood onset, or carried a D4Z4 allele of very reduced size. Due to the different design 
of these studies it is not possible to pool various observations to obtain a complete or more 
defined picture of clinical features of subjects carrying “very short” D4Z4 allele. Therefore, 
the goal of our research is was to conduct a detailed clinical and molecular characterization 
of index cases carrying 1-3 DRA alleles from Italian National Registry for FSHD. 
The study has been performed on carriers of 1-3 DRA accrued through the INRF by the 
Italian Clinical Network for FSHD (ICNF) from January 2008 to December 2013. Of 850 
index cases from the INRF in December 2013, we identified 114 index cases carrying DRA 
with 1-3 repeats. Family studies were conducted in 66 index cases, in which clinical and 
molecular analysis was extended to all available relatives willing to participate. Screening for 
1-3 DRA was performed in 226 relatives (Figure 11). We defined de novo cases single 
participant with neither parent carrying DRA; when the DRA was detected in one of the 
parents and/or other family members (ie, sibs), we classified the participant as familial. We 
considered participants as not informative when it was not possible to examine their parents 
and/or other informative family members. Informed consent, according to the Declaration of 
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Helsinki, was obtained from each participant enrolled in the study. The clinical examination 
was performed using the standardised FSHD clinical protocol with validated inter-rater 
reliability [Lamperti et al., 2010]. In order to investigate the earliest signs of disease and to 
rule out pre- or perinatal events as possible causes of delayed achieving of motor milestones, 
we designed the Infantile Anamnestic Questionnaire (IAQ) (Annex 3). All data about: (1) 
pregnancy, (2) birth, (3) the prenatal period and first month of life and (4) psychomotor and 
language development were collected in a retrospective manner. Items related to each section 
were scored as normal/altered. We collected anamnestic reports about neurological 
examinations in the first year of life, together with clinical and instrumental data in the 
following years, whenever possible, in 80 cases carrying 1–3 DRA. 
 
In 66 unrelated index cases carrying 1-3 DRA we extended molecular characterization to 
parents and/or other relatives. To this purpose we analyzed 226 subjects clinically and 
molecularly. We found that 26 probands were familial (39.4%) index cases and 40 probands 
were de novo (60.6%)(Graphic 3).  
 
 
 
 
 
 
Figure 11: Preliminary selection of probands/families from the Italian National Registry for 
FSHD (INRF). 	
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Graphic 3: Distribution of de novo and familial index cases, carriers of 1-3 DRA. 
 
Interestingly, the mean age at onset observed among the de novo probands was 8.1 yrs; 
whereas it was 13.1 yrs among familial index cases (table 4). Thus muscle weakness appears 
significantly earlier in de novo cases than in familial (Long-rank p test value=0.020). The 
difference in the onset of disease between two groups was calculated with non-parametric 
Kruskal-Wallis test.  
 
Table 4: Age at onset among de novo and familial index cases, carriers of 1-3 DRA. 
 
 
 
Graphic 4 compares FSHD penetrance between carriers of de novo or familial 1-3 DRA 
calculated with the Kaplan-Meier method. Among subjects carrying a de novo 1-3 DRA the 
risk of developing motor impairment is 65% by age 10, 88% by age 15 and 98% by age 20.  
Among subjects carrying a familial 1-3 DRA the risk is 38% by age 10, 77% by age 15 and 
88% by age 20. Therefore the risk of developing FSHD in childhood, before age 10, is 
significantly higher in subjects carrying a de novo 1-3 DRA.  
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Graphic 4:  Age-specific cumulative risk of reported age at onset between de novo and familial index 
cases, carriers of 1-3 DRA. Blue line refers to de novo index cases carriers of 1-3 DRA, red line refers to 
familial index cases carriers of 1-3 DRA.  Long-rank test p value=0.026. 
 
 
It has been reported that alleles of extremely short dimension (1-3 D4Z4 repeats) are 
associated with most severe form of disease [Jardine et al, 1994; Lunt et al, 1995; Ricci et al, 
1999; Ricci et al, 2013]. 
Considering the observed differences in age at onset between de novo and familial 1-3 
DRA carriers, we tested whether the disease expression is more severe in de novo index 
cases. To this aim, we measured the motor disability by the FSHD score [Lamperti et al, 
2010] in de novo and familial index cases. Statistical evaluation failed to detect any 
significant difference in mean FSHD score between the two groups (de novo vs familial 
index cases, 9.7 vs 11.1; Long-rank p test value=0.145). 
Statistical evaluation failed also to detect any significant difference in mean FSHD 
score adjusted by sex and age, between the two groups (de novo vs familial index cases, 9.7 
vs 11.1; Long-rank p test value=0.145) (Graphic 5). 
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Graphic 5: FSHD score in correlation to the age at examination. Red spots refer to de novo index cases 
carriers of 1-3 DRA, green spots refer to familial index cases carriers of 1-3 DRA. 
 
By using the Kaplan-Meier method (Graphic 6) we further evaluated the relative risk of 
loss of independent walking, considered as an important feature of motor disability, in 
carriers of de novo rearrangement and familial index cases. Our analysis showed that the 
cohort of de novo carriers has a higher risk of loss of independent walking versus the familial 
index cases, even though this difference did not reach a statistically significant value. 
 
 
 
Graphic 6: Age-specific cumulative risk of reported loss of independent walking between novo and 
familial index cases, carriers of 1-3 DRA.Blue line refers to de novo index cases carriers of 1-3 DRA, red line 
refers to familial index cases carriers of 1-3 DRA. Long-rank test p value=0.062. 
 
In familial cases analysis was also extended to 42 relatives carrying a DRA. We 
compared the age of the disease onset detected in the group of probands with that recorded in 
the group of relatives. This comparison displayed that affected relatives present a later onset 
of FSHD than the probands (relatives versus probands, 17.6 yrs vs 13.1 yrs (Graphic 7). 
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Long-rank p test value=0.019). We also compared the degree of motor impairment, recorded 
as FSHD score, detected in the two groups. The mean FSHD score received by relatives was 
significantly lower than that recorded in probands (6.1 vs 10.5, Long rank test p 
value<0.0001). Four relatives (6.1%), respectively aged 33, 42, 47, 50, did not present any 
muscle weakness.   
                
 
 
 
 
 
 
 
 
 
 
 
 
 
We gathered anamnestic data about pregnancy, delivery and birth from all participants who 
were able to respond to this questionnaire. We interviewed 80 cases carrying 1–3 DRA. 
No significant alterations in pregnancy, delivery and birth were reported. There was no report 
of any floppy infant at birth. In 72 of 80 participants (90%), psychomotor development 
milestones were reached appropriately. This analysis shows that children carrying 1-3 DRA 
do not display signs of muscle weakness prenatally or at birth. Moreover, signs that can 
possibly be attributed to early onset of muscle weakness are reported only in a small 
percentage of participants. Therefore we conclude that very early onset is not a frequent 
feature of FSHD. Thirteen participants suffered from sensorineural deafness (21.3%). In 
eight cases, it was isolated, with no other recognisable medical condition, and in five cases 
we detected additional extra-muscular manifestations. In four cases, we observed Coats’ 
retinopathy (6.6%). In one it was found as an isolated condition, whereas in three other cases 
it was associated with sensorineural deafness or cognitive impairment. Cognitive impairment 
was reported in six cases (9.8%), and two of these also suffered from epilepsy. All cases with 
mental retardation showed a very severe form of disease (Table 5). 
	
Graphic 7: The distribution of probands and their relatives by the reported age at onset.	
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Table 5 
 
In conclusion our analysis, first showed that the majority of carriers of 1-3 DRA (60.6%) are 
de novo. Notably, this percentage is higher than that previously described in the whole FSHD 
population [Padberg 1982; Padberg et al, 1995; Zatz et al, 1995 ; Tawil et al, 1996;  Zatz et al 
1998; van der Maarel et al, 2000]. We verified the percentage of de novo cases among 4-8 
DRA probands from the INRF and surprisingly identified only 14 (5.7%) out 246 index 
cases, carrying 4-8 DRA. Thus we concluded that among probands from the INRF, carriers 
of de novo rearrangements are significantly more frequent in the cohort of subjects carrying 
1-3 DRA, than in the cohort of 4-8 DRA carriers. This data, associated with the observation 
that previously 1-3 DRAs have never been detected in general population [Scionti et al, 
2012], support the idea that the D4Z4 repeat array is highly recombinogenic and therefore 
prone to high mutation rate. Second, we found that the majority of cases presenting disease 
onset before age 10, are isolated and carry a de novo rearranged DRA (Table 4); while the 
majority of familial cases develops FSHD around the second decade of life. Interestingly, 
among the 66 carriers of 1-3 D4Z4 alleles 6.1% were asymptomatic (Graphic 7). However, 
even though there is a trend towards a more severe progression among de novo cases in 
comparison with familial probands (Graphic 4 and Graphic 6) and infantile disease onset is 
more common among de novo carriers of 1-3 DRA (Table 4), we failed to observe a 
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significant difference in disease outcome between the two groups (mean FSHD score in de 
novo versus familial index cases, 9.7 vs 11.1).  In addition it is important to emphasize that in 
this cohort of subjects carrying the shortest D4Z4 allele, not all presented an infantile onset. 
Indeed 45.5% of index cases reported age at onset after 10 years of age, moreover our 
Anamnestic Infantile Form revealed no presence of the congenital form of the FSHD.  
Collectively, our genotype-phenotype study on the large cohort of subjects carrying the 
shortest allele, revealed that:  
1) first signs and/or symptoms were not detected in pre- and peri-natal period;  
2) only half of the subjects carrying 1-3 DRA develop FSHD in infantile period (1-10 years); 
 3) not all subjects carrying 1-3 DRA display more severe form of disease, regardless 
infantile onset; 
 4) asymptomatic individuals were found to carry 1-3 DRA. 
 These observations suggest that additional factors might contribute to complex FSHD 
pathogenesis. 
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SECTION 3: a novel clinical tool 
From the article: “A novel clinical tool to classify facioscapulohumeral muscular dystrophy 
phenotypes.” 
Ricci G, Ruggiero L, Vercelli L, Sera F, Nikolic A, Govi M, Mele F, Daolio J, Angelini C, Antonini G, Berardinelli A, Bucci E, Cao M, 
D'Amico MC, D'Angelo G, Di Muzio A, Filosto M, Maggi L, Moggio M, Mongini T, Morandi L, Pegoraro E, Rodolico C, Santoro L, 
Siciliano G, Tomelleri G, Villa L, Tupler R. [J Neurol. 2016]  
 
Through the systematic use of the FSHD Clinical Form [Lamperti et al., 2010; Scionti et al., 
2012; Ricci et al., 2013; Nikolic et al., 2016] we recognized that it assesses the severity of 
motor impairment by translating disability into a number (FSHD Evaluation Scale), but it 
does not capture clinical features that may describe various phenotypes. To overcome this 
limitation we integrated several items including typical and atypical features on the basis of 
published reports describing the clinical phenotypes observed in carriers of a DRA [Ricci et 
al., 2014]. Typical and atypical clinical features were combined in the Comprehensive 
Clinical Evaluation Form (CCEF). The definition and the validation of the CCEF were 
performed in two steps. We first recruited 106 subjects carrying a DRA with 1-9 units (11-38 
kb) to test the clinical application of this new tool. The recruitment was based on 452 
subjects examined by the Italian Clinical Network for FSHD (ICNF) in two-year time-
window (2008-2009). Subjects were invited by consecutive phone calls following the order 
of the previous recruitment. We called those near the clinical centers of Modena, Turin and 
Naples. The latter choice was made to avoid people a long-distance trip. We organized three 
meetings dividing the 106 available subjects into three groups on the basis of their 
geographical location (Northern, Central and Southern Italy). Twelve experienced clinicians 
of the ICNF were selected according to their geographical location, so that four neurologists 
examined patients from each one of the three groups. The four selected neurologists used the 
CCEF to evaluate each subject of a single group independently. The results of this first round 
of clinical applications were discussed in a subsequent meeting. We revised the emerged 
critical points, i.e. some difficulties in establishing mild facial weakness, and approved the 
final version of the CCEF (Annex 5). Then, in a second round the inter-rater reliability in 
assigning patients to different phenotypic categories by using the new CCEF was tested. Two 
clinicians, selected by drawing lots, examined additional 56 subjects (Table 6) recruited from 
the cohort of 452 subjects as described above. The two clinicians administered the functional 
motor evaluation test of the Evaluation Form (Annex 5, Section 1, parts b and c) to each 
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subject and calculated the FSHD clinical score on the basis of the FSHD Evaluation Scale, 
previously validated [Lamperti et al., 2010]. Then, the two clinicians completed the Clinical 
Diagnostic Form (CCEF Section 3) and assigned each subjects to one of the nine clinical 
subcategories (CCEF Section 4) independently. A tutorial for the clinical assessment is 
available at www.fshd.it. It takes 20 minutes to collect clinical information and complete the 
neurological evaluation. 
Signed informed consent from patients was obtained before inclusion in the study [Ricci et 
al., 2016]. 
Statistical analysis 
Assessment of the CCEF inter-rater reliability. The inter-observer reproducibility between 
the two examiners respect to the four and nine CCEF categories was assessed using the kappa 
statistics [Fleis, 1981]. Kappa value scores are interpreted as follows: kappa value 1.0 = 
perfect agreement; kappa value ≥ 0.75 < 1.0 = excellent; kappa value > 0.40 <0.75 = good; 
kappa value ≤ 0.40 = poor. The 95% confidence intervals of kappa statistics were calculated 
using the (biased corrected) bootstrap resampling method [Lee and Fung, 1993]. 
 
Table 6. Characteristics of the 56 FSHD patients enrolled in the CCEF inter-rater reliability 
study. 
 
Patients 
 
Number 
(n) 
 
Percentage 
(%) 
 
Sex Male 27 48.2 Female 29 51.8 
    Age at 
examination 
(years) 
14-40 19 33.9 
41-60 20 35.7 
61-74 17 30.4 
    
FSHD score 
0-5 28 50.0 
6-10 21 37.5 
11-15 7 12.5 
    
D4Z4 allele size 
(U) 
1-3 7 12.5 
4-6 38 67.9 
7-8 8 14.3 
9-10 3 5.4 
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The CCEF consists of four sections. The first section, the Evaluation Form (Section 1, Annex 
5), investigates the subject’s clinical history (part a), evaluates the patient’s disability (part b) 
and assesses muscle segmental involvement by using the Medical Research Council (MRC) 
scale (part c). The other sections include the FSHD Evaluation Scale (Section 2, Annex 5), 
the Clinical Diagnostic Form (Section 3, Figure 12) and the Clinical Categories (Section 4, 
Figure 13). 
Several items are examined in the Evaluation Form section. 
- Family history. Questions such as “did/does any of your relatives have a posture like 
yours?”, “was any of your relatives sleeping with half-open eyes?” are asked to identify 
subjects with possible muscle weakness suggestive of FSHD.  
- Evaluation of age at onset. To obtain a more objective evaluation of age at onset and the 
type of muscle initially affected, we introduced specific questions, such as “have your 
relatives ever noticed that you were sleeping with half-open eyes?”, “when have you noticed 
the appearance of winged scapula?”, “have you ever noticed thinness of upper arms or a 
dropped shoulder?”, “have you ever noticed asymmetry of the mouth or smile when looking 
in a mirror or in past photographs from childhood?”. 
- Functional motor evaluation. For a precise description of the distribution of muscle 
weakness, the CCEF evaluates: a) the presence of widened palpebral fissures; orbicular oris 
weakness, horizontal smile; inability to protrude lips, to puff out cheeks, to close eyes and 
bury the eyelashes (facial weakness); b) the maximum degree in abducting arms (scapular 
girdle weakness); c) the ability to climb 4 stair-steps, to stand up from a chair, to rise from 
the floor, to walk (pelvic girdle weakness); d) the ability to walk on tiptoes and/or heels 
(distal legs weakness); e) the presence of Beevor’s sign (abdominal muscles weakness). 
- Evaluation of segmental muscle strength by MRC scale. Fourteen muscle groups are 
examined. Neck extensors are evaluated as single muscle group; external-rotator muscles of 
upper limb, triceps, biceps, common finger extensors, wrist extensors, long fingers flexors, 
wrist flexors, gluteus maximum, iliopsoas, quadriceps, biceps femoris, triceps surae, tibialis 
anterior are evaluated on both sides. 
- Annotation of typical signs. Shoulders with symmetric/asymmetric winging on attempted 
shoulder abduction or forward flexion, straight clavicles, forward sloping of shoulders at rest, 
axillary creases reflecting pectoral muscle wasting, sunken or flattened appearance of the 
chest, “poly-hill sign” with neck, shoulders and arms observed from behind in fullest possible 
abduction (70–90°), with external rotation of the shoulders, hyperlordosis. 
- Annotation of atypical signs. Palpebral ptosis, myotonic phenomenon, muscle rippling, 
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weakness of extra-ocular, masticatory, pharyngeal and lingual muscles, bent spine syndrome, 
early contractures, pes cavus , dropped head, myoglobinuria and persistently high CK values 
above the level of 1000 U/L are considered atypical signs. The presence of cardiomyopathy 
and a respiratory restrictive insufficiency at onset or in subjects still walking (FSHD score 
<12) is also considered an atypical sign [Ricci et al., 2014]. 
The Evaluation Form allows completing the FSHD Evaluation Scale to calculate the FSHD 
clinical score (Section 2, Annex 5) [Lamperti et al., 2010]. The score considers the regional 
distribution of muscle weakness and the functionality of: (I) facial muscles (scored from 0 to 
2); (II) scapular girdle muscles (scored from 0 to 3); (III) upper limb muscles (scored from 0 
to 2); (IV) leg muscles (scored from 0 to 2); (V) pelvic girdle muscles (scored from 0 to 5); 
and (VI) abdominal muscles (scored from 0 to 1). Overall, the total FSHD score ranges from 
0 to 15 and numerically defines the clinical severity of the motor impairment.  
All sections of CCEF are used for the assessment and the classification of a patient. Based on 
the distribution of muscle weakness, scored by the FSHD Evaluation Scale, and the 
combination of the clinical features suggestive or not of FSHD, summarized in the Clinical 
Diagnostic Form (CCEF Section 3, Figure 12), it is possible to assign patients to different 
phenotypic categories (CCEF Section 4, Figure 13). In particular, we assigned 1) subjects 
with typical FSHD presenting facial and scapular girdle muscle weakness in category A; 2) 
subjects with muscle weakness limited to facial or scapular girdle muscles in category B; 3) 
asymptomatic subjects without motor impairment in category C; 4) subjects with myopathic 
phenotype presenting other anomalous clinical features not consistent with FSHD in category 
D. 
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Figure 12: CCEF Section 3, Clinical Diagnostic Form. 
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Figure 13: CCEF Section 4, Clinical Categories. 
 
 
Moreover, in view of our experience on FSHD phenotypes accrued through the past years in 
INRF [Ricci et al., 2013; Nikolic et al., 2016], we further described additional variants within 
each category (Figure 13, Figure 14). Patients with typical phenotype were classified in three 
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subcategories (A1, A2, A3), on the basis of the severity of facial involvement, which seems 
to discriminate some classical phenotypes (Figure 14A-C). This is because we observed that 
some infantile forms or more severe phenotypes [Nikolic et al., 2016] are characterized by an 
early and prominent weakness of orbicularis oculi and oris with facial diplegia and dysartria. 
Thus, these patients were defined as category A1 to distinguish them from the vast majority 
of patients in which we observed a milder facial involvement (categories A2 and A3). This 
distinction should facilitate the identification of a specific clinical group deserving ad hoc 
studies.  Incomplete FSHD phenotype, not presenting a coexisting involvement of facial and 
scapular girdle muscles without other uncommon features, are considered category B1 or B2 
(Figure 14D, E). We identified these categories because, for instance, an isolated scapular 
girdle muscle weakness can be observed in FSHD relatives, but it can be also related to other 
myopathic disorders or nerve injuries.  
Category D comprises myopathic subjects presenting some FSHD features in association 
with other uncommon characteristics suggestive of a possible comorbidity (D1) or patients 
that do not fulfill the diagnostic criteria for FSHD and can be affected by an alternative 
disease (D2) (Figure 14H,I). Atypical features were chosen based on evidences from 
literature [Ricci et al., 2014]. This category may facilitate the discovery of factors that 
contribute to the disease expression or identify those subjects who are wrongly considered 
FSHD because of a diagnostic bias due to the random finding of DRA.  
Finally, we decided to further differentiate non penetrant carriers: the asymptomatic subjects 
without motor impairment that present minor signs suggestive of FSHD (“Typical features-
Other signs” Figure 12) are described as category C1, whereas category C2 includes subjects 
with a neurological examination completely normal (Figure 14F,G). This distinction might be 
of particular importance for studying the natural history of disease (i.e. subjects described as 
C1 might develop clinical FSHD later or remain asymptomatic). 
Overall, the categories we generated aim at describing different phenotypes thus capturing 
clinical diversity, regardless the severity of motor impairment, otherwise reported as FSHD 
score.  
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Figure 14: Examples of clinical categories: case reports. a Category A1: male, 38-year old, 
showing severe upper and lower facial weakness (unable to close both eyelids completely, 
puff cheeks and protrude lips), and impairment of upper limb abduction with winged scapula. 
b Category A2: female, 31-year old, with moderate upper (partial ability to close eyes, 
without the presence of widened palpebral fissures) and lower facial weakness (partial 
ability to puff out cheeks), impairment of upper limb abduction with winged scapula. c 
Category A3: male, 60-year old, with moderate lower facial weakness (partial ability to 
protrude lips), impairment of upper limb abduction with winged scapula. d Category B1: 
male, 66-year old, with impairment of upper limb abduction with winged scapula, no facial 
weakness. e Category B2: female, 34-year old, with moderate lower facial weakness (partial 
ability to puff out cheeks and to protrude lips), no scapular weakness. f Category C1: female, 
55-year old, presenting asymmetric scapular winging on forward flexion without motor 
impairment (FSHD score 0). g Category C2: male, 56-year old, without motor impairment or 
other FSHD typical signs of muscle atrophy/weakness (FSHD score 0). h Category D1: male, 
66-year old: onset after 50 age at shoulder girdle, without facial motor impairment and 
‘‘bent spine’’. i Category D2: male, 75-year old, with isolated bent spine syndrome, without 
signs suggestive of FSHD 
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The concordance between the clinical assessments performed by the two neurologists was 
evaluated for the nine CCEF categories described in Figure 13. As shown in Table 7, a 
good/excellent agreement [Kappa = 0.75; 95% CI (0.57; 0.87)] was observed using the nine 
CCEF classifications. The overall kappa statistic combine the reliability of the nine 
categories with a perfect agreement observed for categories B2, C2, D1, D2; a good/excellent 
agreement for categories A1, A2, B1 and C2, and a good agreement observed for the 
category A3. The results of the concordance of the final four CCEF categories are presented 
in Table 8. As expected, the reliability increased with a kappa equal to 0.90; 95% CI (0.71; 
0.97). A perfect agreement was observed for categories C and D, an excellent agreement for 
categories A [Kappa = 0.88; 95% CI (0.75; 1.00)], and a good agreement for categories B 
[Kappa= 0.79; 95% CI (0.57; 1.00)]. A lower level of kappa, when compared with values 
obtained for each subcategory, is due to the increased number of categories taken into 
account in the final score and reflects the sensitivity of the test. 
 
Table 7: Agreement between Observer 1 and Observer 2 with respect to the nine CCEF 
categories classification. 
 
Kappa=0.75; 95% CI (0.57; 0.87) 
 
 
Observer 2 
CCEF categories A1 A2 A3 B1 B2 C1 C2 D1 D2 Total 
O
bs
er
ve
r 
1 
A1 6 2 0 0 0 0 0 0 0 8 
A2 1 18 2 0 0 0 0 0 0 21 
A3 0 2 4 2 0 0 0 0 0 8 
B1 0 0 1 5 0 0 0 0 0 6 
B2 0 0 0 0 2 0 0 0 0 2 
C1 0 0 0 0 0 2 0 0 0 2 
C2 0 0 0 0 0 1 4 0 0 5 
D1 0 0 0 0 0 0 0 2 0 2 
D2 0 0 0 0 0 0 0 0 2 2 
Total 7 22 7 7 2 3 4 2 2 56 
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Table 8: Agreement between Observer 1 and Observer 2 with respect to the fourth CCEF 
categories classification. 
 
 
 
 
 
 
 
 
 
 
 
Kappa=0.90; 95%CI (0.71; 0.97) 
 
The genetic heterogeneity in FSHD requires the harmonized classification of clinical phenotypes 
among patients and within families to serve clinical practice. In FSHD intra-familial clinical 
variability is one of the most relevant challenges affecting clinical practice and genetic counseling. 
Our work shows that the CCEF is an easy clinical tool useful to capture various phenotypes from 
classic FSHD to individuals with incomplete phenotype, or asymptomatic carriers as well as 
subjects with atypical signs for which alternative diagnoses may be supposed. The choice of the 9 
categories responds to the necessity of describing the wide clinical spectrum of FSHD patients and 
their relatives with a simple and direct approach. By applying the CCEF it will be possible to 
quickly classify families on the basis of the harmonized description of genotypes and phenotypes. 
This classification will support genetic counseling taking into account disease penetrance and 
expression within a single family. Figure 15 shows some examples. Figure 15A displays a family 
with the canonical autosomal dominant pattern of inheritance. The disease is present in all three 
generations and all subjects, carrying a DRA, display facial and scapular girdle weakness typical of 
FSHD, categories A2 and A3. Figure 15B shows a family in which two sibs are severely affected 
(A1) whereas the father carrying the same 3U DRA (no somatic mosaicism of the DRA was 
detected) is healthy (C2). Figure 15C presents a four-generation pedigree in which a single 29 yrs 
old subject, III.2, developed mild weakness of orbicularis oris and weakness of scapular girdle 
muscle (category A3). She carries a 6U DRA inherited by her healthy 55 yrs old father, II.2, 
(category C2). The paternal 37 old yrs aunt, carrying the 6U DRA, is asymptomatic with non-
 
Observer 2 
 
CCEF 
categories A B C D Total 
O
bs
er
ve
r 
1 
A 35 2 0 0 37 
B 1 7 0 0 8 
C 0 0 7 0 7 
D 0 0 0 4 4 
Total 36 9 7 4 56 
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specific signs as horizontal clavicles and axillary creases (category C1) and the paternal 72 yrs old 
grandmother, I.2, carrying the 6U DRA, presents only incomplete and mild weakness of facial 
muscle (category B2). Figure 15D describes a family with a single patient presenting severe 
myopathy with atypical phenotype (D2). The 63 yrs old proband carries a DRA with 9 units as do 
the twin brother and the 70 yrs old sister, both healthy (C2). Finally, Figure 15E displays a family 
that may mimic an autosomal dominant inheritance. The proband (II.5), carrying a DRA, presents a 
typical FSHD phenotype (A3). His mother (I.2) carries the same DRA, but she displays an atypical 
phenotype (D1) without the facial muscle involvement and with an early and predominant 
involvement of the pelvic girdle probably related to old age. Instead his two older sisters (II.1 and 
II.2) are asymptomatic carriers. All these unexpected distribution of clinical phenotypes require 
particular attention in evaluating the risk of disease onset and expression and the possible 
contribution of genetic modifiers. Indeed the systematic application of the CCEF might support 
physicians in the identification of these critical families that might be suitable for further 
investigations and promote the understanding of disease pathophysiology. Moreover by using the 
CCEF it is possible to obtain the longitudinal trajectory of disease progression for each patients and 
describe the disease’s natural history, including the follow-up of non-manifesting carriers. 
Overall, the CCEF is a flexible tool that can assist novel strategies to study the etiology of rare 
diseases. It can support a catalogue of the phenotypes observed among and within families 
facilitating the phenotypic stratification of FSHD patients, the search of genetic modifiers, and 
studies on the natural history of disease. Finally, the harmonized clinical classification of subjects is 
fundamental for the stratification of patients eligible for clinical trials. In this perspective the CCEF 
can be an instrument for observational studies or randomized clinical trials [Ricci et al., 2016, 
Annex 6].  
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Figure 15: Clinical characterization of families in which a DRA segregates. Five families are 
presented. For each subject carrying a 4qA-type DRA, age at evaluation, size of the DRA, clinical 
category and FSHD score are reported. 
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SECTION 4: the next step to dissect the genetic and clinical complexity of FSHD 
 
From the article: Clinical expression of facioscapulohumeral muscular dystrophy in carriers of 33-
35 kb D4Z4 reduced alleles: experience of the Italian National Registry for FSHD. 
 
Ruggiero L, Mele F , Ricci G, Vercelli L, Govi M; Nikolic A, Louise M, Sera F, Bruzzese D, Berardinelli A, Angelini C; Antonini G, Bucci E, Filosto 
M, Cao M, Giardina E, Pegoraro E, Di Muzio A, Telese R, Maggi L, Portaro S, Rodolico C, Villa L, Mongini T, Siciliano G, Tomelleri G, D’Angelo 
G, Maioli MA, Moggio M, Santoro L, Rossella Tupler. [To be submitted]  
 
Methods 
 
Study design and subject selection 
We performed an observational study of 152 probands (P) and 223 relatives (R) from a consecutive 
group of 252 probands and 306 relatives, carriers of 8-10 DRA, from the Italian National Registry 
for FSHD collected between 2008 and 2016. Informed consent, according to the Declaration of 
Helsinki, was obtained from each participant enrolled in the study. 
 
Clinical Examination 
In this large cohort we applied the Comprehensive Clinical Evaluation Form (CCEF). Based on the 
distribution of muscle weakness and the combination of the clinical features suggestive or not of 
FSHD, it is possible to assign patients to different Phenotypic Categories. In particular, we assigned 
subjects with typical FSHD presenting facial and scapular girdle muscle weakness without atypical 
features in category A; subjects with muscle weakness limited to facial or scapular girdle muscles in 
category B; asymptomatic subjects without motor impairment in category C; subjects with 
myopathic phenotype presenting other anomalous clinical features not consistent with FSHD in 
category D.  
 
Molecular characterisation  
Allele sizes were estimated by Southern hybridization using probe p13E-11. Genomic DNA 
extracted from peripheral blood lymphocytes was digested with EcoRI, EcoRI/BlnI or XapI, 
electrophoresed in a 0.4% agarose gel for 45–48 h at 35 V alongside an 8–48 kb marker (Bio-Rad) 
as previously described [Scionti et al., 2012]. To assess the chromosomal origin of D4Z4-reduced 
alleles, DNA from each subject was analysed by NotI digestion and hybridization with the B31 
probe [Scionti et al., 2012]. Restriction fragments were detected by autoradiography or using a 
	 58	
Typhoon Trio system (GE Healthcare). 4qA/4qB allelic variants were defined using HindIII-
digested DNA, pulsed field gel electrophoresis electrophoresis and Southern blot hybridization with 
radiolabeled 4qB and 4qA probes according to standard procedures [Scionti et al., 2012]. 
The Simple Sequence Length Polymorphism (SSLP) and the pLAM Single Nucleotide 
Polymorphism (SNP) [AT(T/C)AAA] sequences flanking the D4Z4 repeat units were defined in 
294 relatives according to published procedures [Scionti et al., 2012].  
 
Statistical Analysis  
The genotype-phenoptype correlations analysis was performed using the following statistical tests:  
- p value: for evaluation of difference distribution between males and females in the clinical 
categories, to compare the age at onset between index cases and relatives and between the 
age at last neurological examination of asymptomatic relatives and age at onset of 
symptomatic relatives. Finally, to compare the FSHD score between index case and 
relatives. 
- t test: to compare the age at onset and the FSHD score between males and females in the 
group of index cases and relatives.   
- Anova test: to compare the age at onset between classical FSHD and atypical FSHD in the 
group of index cases and relatives.   
 
Results 
Phenotypic characterization of index cases and relatives carrying 7-8 DRA 
We re-evaluated 152 unrelated index cases [84 males, 70 females, mean age at last neurological 
examination 53,8 ± 15,4 (range 8-87)], in males mean age was 49.8, in females was 57,9. Starting 
from index cases, we identified 223 relatives carriers 7-8 DRA (99 males and 124 females, mean 
age at last neurological examination 45,5 ± 17,3). The percentage of carriers of 33 kb DRA was 
46% while of carriers of 35 kb DRA 53%, with a similar distribution of subject in two genetically 
subgroup (table 9). 
  
	 59	
 
Table 9: Characteristics of the 251 index cases and 310 relatives carriers 7-8 DRA. 
 
 
 
 
 
 
  
 
Index Cases Relatives 
N subject entrolled 251 310 
N subject revalued 154 221 
M 84 95 
F 70 126 
Mean age at 
examination 53,8 45,5 
Carriers 33 kb DRA 45% 49% 
Carriers 35 kb DRA 55% 51% 
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Distribution of clinical categories of index cases 
The distribution of probands in the clinical categories shows that 50,7% (n=77) of subjects display a 
classic FSHD phenotype, classified as category A. Interestingly, among these 77 cases, only 3 
presented severe facial weakness, classified as category A1, 41 showed a moderate facial weakness 
(category A2) and 27 were characterized by a partial facial involvement (category A3). An 
incomplete FSHD phenotype (category B) has been observed in 32 index cases (20,7%). The 
majority of this subgroup (n: 30) is composed by patients with shoulder involvement without facial 
weakness (category B1). Whereas the isolated facial weakness was detected only in 2 subjects 
(category B2). Finnaly, 37 index cases (28.6%) presented phenotypes with clinical features not 
consistent with FSHD and were listed as category D. In particular 5 subjects showed a phenotype 
not consistent with FSHD, but suggestive of an alternative diagnosis (category D2) and 36 
presented additional uncommon clinical signs suggestive of a possible comorbidity (category D1) 
(Graphic 8 A). Interestingly, we did detect a significant difference of distribution between males 
and females in the clinical categories (p-value 0,019). The atypical phenotypes are more frequently 
in women group (Graphic 9).  
 
Distribution of clinical categories of relatives 
 
The distribution of relatives in the clinical categories shows that 52.7% of subjects were 
asymptomatic, classified as category C. In particular 85 showed a neurological examination 
completely normal (category C2), while 31 present minor signs (category C1) without motor 
impairment. On the other hand only 38 (15.9%) of realtives display a classic FSHD phenotype 
(category A). Interestingly, anyone was in category A1, 18 were in category A2 and 20 in category 
A3. We observed the shoulder involvement without facial weakness in 25 subjects, whereas the 
isolated facial weakness was detected in 29 subjects. Overall 24% of relatives displayed an 
incomplete phenotype. Finally, 15 relatives presented additional uncommon characteristics 
suggestive of a possible comorbidity (category D1) and 7 with clinical features not consistent with 
FSHD (category D2). The distribution of index case and relatives in different clinical category is 
synthesized in (Graphic 8) 
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Graphic 8: the distribution of index cases (part A) and relatives (part B) in the clinical category 
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Graphic 9: the comparison of distribution of clinical category between male and female in the group of index 
cases 
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Analysis of clinical categories in families 
Based on the clinical category of index case, we assessed the clinical patterns of relatives (table 10) 
and we observed that only in 1/99 of our families, all analyzed subjects displayed classical FSHD 
phenotype. In contrast, in about a third of our families (36/99) the index case only presents 
myopatic phenotype, moreover in these families all relative carriers 7-8 DRA are non-penetrant. 
Finally, it is important to emphasize that if the proband is classified as “B” or “D” we do not find 
relatives with classic FSHD phenotype. 
 
(Table 10): Evaluation of clinical patterns of relatives on the basis of clinical category of proband 
 
 
       Clinical Category Probands 
Clinical patterns Familiars A B D Total 
A 1 0 0 1 
AB 1 0 0 1 
ABC 5 0 0 5 
ABCD 2 0 0 2 
AC 7 1 2 9 
ACD 1 0 0 1 
B 5 2 2 9 
BC 8 6 3 17 
BCD 3 1 1 5 
C 16 6 14 36 
CD 2 2 3 7 
D 4 1 0 5 
Total 55 19 25 99 	
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Age at onset  
We observed that 62% of index cases present the first symptoms after 20 years old (mean 33,2 
±18.5). We did detect a significant difference between males and females (in males age at onset was 
29,4 ±17,2 while in females 38,1 ±18.9; T test p-value: 0,002). Moreover, we evaluated the mean 
age at onset of index cases for each category and we observed that subject with classical FSHD 
phenotype had a significantly earlier onset than subjects with atypical FSHD phenotype (classical 
FSHD 28.4 ±17.3, in contrast atypical FSHD 42.6 ±17.8; Anova p-value >0.001) (Graphic 10). 
Interestingly, we found the same statistical significant data in the group of relatives (males age at 
onset 26.4 ±12.8 while females 38.7 ±18.1; t-test p-value 0,003; classical FSHD 29.7±18.1 while 
atypical FSHD 45.2 ±16.3, Anova p-value: 0.017) (Graphic 11). In line to these data when we 
compared the age at onset between index cases and relatives we did not detect a significant 
difference (index cases 33,2 ±18.5, and relatives 34.6 ±17.4; p-value 0.6). Instead the age at last 
neurological examination of asymptomatic relatives (39,2) was result significantly older respect the 
mean of age at onset of symptomatic relatives (p-value >0.01).  
Finally, we observed that the 70% of patients present with scapular girdle weakness at onset, in 
contrast patients with facial weakness at onset are only 12 (5%). A considerable percentage of 
patients present pelvic girdle weakness at onset (13,7%) and in this subgroup the large majority 
25/31 are women.  
 
 
Graphic 10: the evaluation of age at onset in the group of index cases on the basis clinical category and sex  
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Graphic 11: the evaluation of age at onset in the group of relatives on the basis clinical category and sex  
 
Severity of motor impairment  
The degree of motor impairment among index cases was also evaluated, using FSHD clinical score. 
The mean FSHD score was 5.8 ±3.3. We did not detect evidence of a difference in term of FSHD 
score among males and females (males mean FSHD score 6 ±3.2, females FSHD score 5.6 ±3.3). 
Finally, we did detect a difference of FSHD score between index cases and relatives (p-value 
<0.001), in fact the last ones present less severe clinical impairment (mean FSHD score 3.6 ±3.1) 
(Graphic 12). 
 
 
Graphic 12: the degree of motor impairment of index cases and relatives and the comparison between sexs. 
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Graphic 13: the degree of motor impairment among index cases evaluated in association with clinical category 
and age at examination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graphic 13: the degree of motor impairment among relatives evaluated in association with clinical category and 
age at examination. 
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Discussion:  
FSHD 1 is a complex disease with peculiar clinical and genetical aspects. It is reported a wide 
variability of clinical expression, both in term of age at onset, severity of motor impairment and 
progression [Mul et al., 2017]. In addition, several studies have reported high percentage, ranging 
between 25-30%, of non-penetrant carriers, making uncertain the prognosis for subjects carrying or 
at risk of carrying D4Z4 reduced alleles [Tonini et al., 2004].  
This complexity was generated by a difficult application and interpretation of molecular test. First 
of all, a positive result of the genetic test has been considered sufficient for definite diagnosis of 
FSHD regardless of the clinical characterization of subjects. Unexpectedly, by revising the 
literature the molecular signature of FSHD turned out poorly specific and sensitive [Nguyen K et al 
2017; Scionti et al. 2012, Tawil et al., 2015]. Instead, before the discovery of genetic signature, the 
diagnosis was entirely based on clinical evidence.  
However, the cited studies showed an inverse correlation between the number of D4Z4 repeats and 
the severity of the disease. Alleles with 1-3 D4Z4 repeats are generally associated with a severe 
form of disease that presents in childhood, 4-8 D4Z4 repeats are associated with the classical form 
of FSHD, and 9-10 D4Z4 repeats with a milder disease [Lunt et al., 1995a; Tawil et al., 1996; Ricci 
et al., 1999]. DRA between 38 and 45 kb in size (9-11 D4Z4 repeats) have been described both in 
normal and affected individuals and are considered as borderline [Butz et al., 2003; Vitelli et al., 
1999]. This last group of patients with milder phenotype seems to be in expansion including also 7-
8 DRA carriers [Statland et al., 2015]. 
The present study is the largest standardized genotype-phenotype correlation analysis of index cases 
and relatives carriers of 7-8 DRA. 
The first objective of our study was to evaluate the distribution of index cases in the different 
phenotypic categories. Very interestingly, we observed that only 50.7% of probands have the 
classic FSHD phenotype (category A). In addition, only 3 of 154 index cases have a severe facial 
involvement (category A1) and the facial weakness at onset is a very rare report. These data 
confirm that in this subgroup of patients the facial involvement is less frequent and less severe than 
in subjects carrying a smaller fragment [Felice et al., 2000]. Moreover, it is even more important to 
emphasize that frequently these patients present incomplete phenotypes without facial involvement 
(B1) or with atypical signs (category D). The clinical pattern of the relatives of index cases 
belonging to the B1 and D group did not show any subject with classic FSHD phenotype. For these 
patients it is mandatory to consider an alternative diagnosis. 
The second objective was to evaluate the distribution of relatives in the phenotypic categories. The 
most important result was that the majority of these subjects (53%) were asymptomatic. This 
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percentage of asymptomatic carriers is much higher than those reported earlier [Tonini et al. 2004]. 
Interestingly, the age at last neurological examination of asymptomatic relatives resulted 
significantly older with respect to symptomatic relatives, so we may suppose that these subjects will 
never develop the disease. A first interesting conclusion is that for appropriate genetic counselling it 
is mandatory to perform systematically clinical and molecular test in the relatives. On the other 
hand, the NGS technology frequently discovers “new” or “note” mutation reported as pathogenic 
witch reveal to be non causative, thus requiring the extension of the molecular test to parents or 
other relatives [Savarese et al. 2016].  
The majority of patients show the first symptoms after 20 years without statistical difference 
between the mean of age at onset for index cases and relatives so we can consider carriers 7-8 DRA 
as “late onset” patients [Zatz et al., 1995, Tawil et.al 1996]. In addition, atypical cases have the 
onset after 40 years and so we could consider them as “very late onset patients”. Moreover, none of 
probands classified as atypical phenotype (category D) had a relative with a classic phenotype 
(category A) and in none of these pedigree we can detect the classic autosomal dominant 
inheritance. Indeed, this subgroup has peculiar features and it is different from classical form of 
FSHD described by Padberg. 
Moreover, it is commonly reported that women have a phenotype milder than men, but the reasons 
for this are still unknown [Tonini et al. 2004; Zatz et.al., 1998]. The evaluation of age at onset 
between males and females in combination with FSHD score and clinical category allows us to 
make another interesting consideration. Women have a later onset and frequently atypical 
phenotype but the degree of disability impairment is comparable between sexes. Therefore, our data 
suggest that some factor exist in woman that delay the symptom onset and influence the phenotype 
but these “protective factor” have a role time-related. Considering this specific trend and the mean 
of age at onset in woman we can hypothesize a crucial role of hormonal factors related to fertile age 
but the data should be confirmed with dedicated studies.  
Globally the evaluation of FSHD clinical score, as before reported, confirms that the carriers of 33-
35 kb DRA have a slight clinical impairment [Statland et al. 2015; Ricci et al., 2013] ,but clinical 
expression of index cases, showed a large variability ranging from subjects minimally affected to 
wheelchair patients. This variability is not completely related to the disease duration, therefore there 
are some other factors that influence the severity of disease at the beginning. Moreover, relatives 
displayed a milder phenotype than proband, supporting the notion that in this subgroup of patients, 
the genetic background plays a role in modulating the disease expression. The degree of disability 
of relatives is related to the age at last neurological examination but it does not depend on the 
disease duration, therefore the presence of co-morbidity may play a decisive role.  
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Conclusion 
1) About 50% of index cases carriers of 7-8 DRA do not present a classic FSHD phenotype. 
Therefore for a good clinical practice, it is necessary to consider alternative myopathy, in particular 
because subjects with atypical phenotype are often sporadic cases. In these way, the association of a 
myopathic phenotype with the D4Z4 contraction may be random. 
2) 53% of relatives carriers 7-8 DRA are non-penetrant and therefore a big careful attention is 
needed in genetic counselling. 
3) To dissect FSHD clinical complexity it is mandatory to associate scales that evaluate the degree 
of disability with tool that evaluate the phenotype 
4) Probably protective factors exist in women but their benefits play a role only during fertile age. 
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